Genetic aspects of ischemic stroke: Coagulation, homocysteine, and lipoprotein metabolism as potential risk factors

Critical Reviews in Clinical Laboratory Sciences

Volumn 47, Issue 2, 2010, Pages 72-123

  Stankovic, Sanja ^a   Majkic Singh, Nada ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Allele; Candidate genes; Haemostasis; HomocysteineApolipoprotein; Ischemic stroke; Mutation; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ABC TRANSPORTER A1; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; CHOLESTEROL ESTER TRANSFER PROTEIN; CYSTATHIONINE BETA SYNTHASE; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; GLYCOPROTEIN VI; LIPOCORTIN 5; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; METHIONINE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR;

ABCA1 GENE; AMINO ACID BLOOD LEVEL; ANX5 GENE; APO A1 GENE; APO AIV GENE; APO AV GENE; APO B GENE; APO CIII GENE; APO E GENE; APO H GENE; BLOOD CLOTTING; CBS GENE; CEREBROVASCULAR ACCIDENT; CETP GENE; F13A1 GENE; F2 GENE; F5 GENE; FGA GENE; FGB GENE; GENE; GENETIC POLYMORPHISM; GP1BA GENE; HEMOSTASIS; HUMAN; ITGA2 GENE; ITGA2B GENE; ITGB3 GENE; LDLR GENE; LIPOPROTEIN METABOLISM; LOX 1 GENE; LPL GENE; MONOGENIC DISORDER; MTHFR GENE; MTR GENE; PON1 GENE; PON2 GENE; PON3 GENE; PRIORITY JOURNAL; PZ GENE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SERPINE1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TAFI GENE; THBD GENE; TPA GENE; VARIABLE NUMBER OF TANDEM REPEAT; VWF GENE;

EID: 77954301768     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408361003791520     Document Type: Review

References (489)

1. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsch EE. Classifcation of subtype of acute ischemic stroke. Defnitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
2. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon J V, Sacco RL; American Heart Association/American Stroke Association Stroke Council; Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Academy of Neurology. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37: 1583-1633.
3. Dichgans M. Genetics of ischaemic stroke. Lancet Neurol 2007; 6: 149-161.
4. Rubattu S, Volpe M, Kreutz R, Ganten U, Ganten D, Lindpaintner K. Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nat Genet 1996; 13: 429-434.
5. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain 2000; 123: 1784-1812.
6. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004; 35: 212-227.
7. Jamrozik K, Broadhurst RJ, Anderson CS, Stewart-Wynne EG. Te role of lifestyle factors in the etiology of stroke. A population-based case-control study in Perth, Western Australia. Stroke 1994; 25: 51-59.
8. Touzé E, Rothwell PM. Sex diferences in heritability of ischemic stroke: a systematic review and meta-analysis. Stroke 2008; 39: 16-23.
9. Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke 2004; 35: 819-824.
10. Humphries SE, Morgan L. Genetic risk factors for stroke: insights into pathophysiology from candidate gene approaches. Lancet Neurol 2004; 3: 227-235.
11. Rauramaa R, Väisänen SB, Luong LA, Schmidt-Trücksäss A, Penttilä IM, Bouchard C, Töyry J, Humphries SE. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Tromb Vasc Biol 2000; 20: 2657-2662.
12. Rundek T, Elkind MS, Pittman J, Boden-Albala B, Martin S, Humphries SE, Juo SH, Sacco RL. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002; 33: 1420-1423.
13. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, De Carli C. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke 2004; 35: 1609-1613. (Pubitemid 38823634)
14. Turner ST, Jack CR, Fornage M, Mosley TH, Boerwinkle E, de Andrade M. Heritability of leukoaraiosis in hypertensive sibships. Hypertension 2004; 43: 483-487.
15. Schmidt R, Fazekas F, Enzinger C, Ropele S, Kapeller P, Schmidt H. Risk factors and progression of small vessel disease-related cerebral abnormalities. J Neural Transm Suppl 2002; 62: 47-52.
16. Zöller B, Dählback B. Linkage between inherited resistance to activated protein C and factor V mutation in venous thrombosis. Lancet 1994; 343: 1536-1538.
17. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutations in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
18. De Maat MP, Kluft C, Jespersen J, Gram J. World distribution of factor V Leiden mutation. Lancet 1996; 347: 58.
19. Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001; 87: 1361-1366.
20. Juul K, Tybjaerg-Hansen A, Stefensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100: 3-10.
21. Kim RJ, Becker RC. Association between factor V Leiden, pro-thrombin G20210A, and methylentetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-957.
22. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004; 61: 1652-1662.
23. Xin XY, Song YY, Ma JF, Fan CN, Ding JQ, Yang GY, Chen SD. Gene polymorphisms and risk of adult early-onset ischemic stroke: a meta-analysis. Tromb Res 2009; 124: 619-624.
24. Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction. Lancet 1995; 345: 795.
25. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinen L, Palomäki H, Kaste M. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Tromb Haemost 1995; 73: 558-560.
26. Lalouschek W, Suess E, Aull S, Schnider P, Uhl F, Zeiler K, Pabinger-Fasching I. Clinical and laboratory data in heterozygous factor V Leiden mutation positive versus negative patients with TIA and minor stroke. Stroke 1995; 26: 1963-1964.
27. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
28. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Tromb Vasc Biol 1995; 15: 783-785.
29. Catto A, Carter A, Grant PJ. Factor V Leiden mutation and completed stroke. Stroke 1996; 27: 573.
30. Albucher JF, Guiraud-Chaumeil B, Chollet F, Cadroy Y, Sié P. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke. Stroke 1996; 27: 766-767.
31. Chimowitz M, Mansbach H, Schmaier A, Nichols W, Ginsburg D. Factor V mutation and cryptogenic stroke in the young [abstract]. Stroke 1996; 27: 188.
32. Fisher M, Fernandez JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A, Grifn JH. Activated protein C resistance in ischemic stroke not due to factor V arginine506->glutamine mutation. Stroke 1996; 27: 1163-1166.
33. Landi G, Cella E, Martinelli I, Tagliabue L, Mannucci PM, Zerbi D. Arg506Gln factor V mutation and cerebral ischemia in the young [letter]. Stroke 1996; 27: 1697-1698. (Pubitemid 26295930)
34. Markus HS, Zhang Y, Jefery S. Screening for the factor-V Arg 506 Gln mutation in patients with TIA and stroke. Cerebrovasc Dis 1996; 6: 360-362.
35. Press RD, Liu XY, Beamer N, Coull BM. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996; 27: 44-48.
36. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125: 265-269. (Pubitemid 126449270)
37. Bentolila S, Ripoll L, Drouet L, Mazoyer E, Woimant F. Trombophilia due to 20210 G→A prothrombin polymorphism and cerebral ischemia in the young. Stroke 1997; 28: 1846-1847.
38. Halbmayer WM, Haushofer A, Angerer V, Finsterer J, Fischer M; Vienna Trombophilia in Stroke Study Group (VITISS). APC resistance and factor V Leiden (FV:Q506) mutation in patients with ischemic cerebral events. Blood Coagul Fibrinolysis 1997; 8: 361-364.
39. Martinelli I, Franchi F, Akwan S, Bettini P, Merati G, Mannucci PM. Te transition G to A at position 20210 in the 3'-untrans-lated region of the prothrombin gene is not associated with cerebral ischemia [letter]. Blood 1997; 90: 3806.
40. Sánchez J, Román J, de la Torre MJ, Velasco F, Torres A. Low prevalence of the factor V Leiden among patients with ischemic stroke. Haemostasis 1997; 27: 9-15.
41. Iniesta JA, Corral J, Fernández-Pardo J, González-Conejero R, Vicente V. Factor-V (Arg506->Gln) mutation in ischemic cerebrovascular disease. Haemostasis 1997; 27: 105-111.
42. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, Tracy R P. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Tromb Haemost 1998; 79: 912-915.
43. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali PA, Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-3565.
44. Lalouschek W, Aull S, Series W, Zeiler K, Mannhalter C. Te prothrombin G20210A mutation and factor V Leiden mutation in patients with cerebrovascular disease. Blood 1998; 92: 704-705.
45. Longstreth WT Jr, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH. Risk of stroke in young women and two pro-thrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29: 577-580.
46. Nabavi DG, Junker R, Wolf E, Lüdemann P, Doherty C, Evers S, Droste DW, Kessler C, Assmann G, Ringelstein EB. Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients. J Neurol 1998; 245: 653-658. (Pubitemid 28439030)
47. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-1797.
48. Iniesta JA, Corral J, Gonzalez-Conejero R, Rivera J, Vicente V. Prothrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease. Headache 1999; 39: 486-489.
49. Lalouschek W, Aull S, Serles W, Schnider P, Mannhalter C, Pabinger-Fasching I, Deecke L, Zeiler K. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. Tromb Res 1999; 93: 61-69.
50. Margaglione M, D'Andrea G, Giuliani N, Brancaccio V, De Lucia D, Grandone E, De Stefano V, Tonali PA, Di Minno G. Inherited prothrombotic conditions and premature ischemic stroke: sex diference in the association with factor V Leiden. Arterioscler Tromb Vasc Biol 1999; 19: 1751-1756.
51. Voetsch B, Damasceno BP, Camargo EC, Massaro A, Bacheschi LA, Scaf M, Annichino-Bizzacchi JM, Arruda VR. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Tromb Haemost 2000; 83: 229-233.
52. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001; 32: 1793-1799.
53. Lopaciuk S, Bykowska K, Kwiecinski H, Mickielewicz A, Czlonkowska A, Mendel T, Kuczynska-Zardzewialy A, Szelagowska D, Windyga J, Schröder W, Herrmann FH, Jedrzejowska H. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Tromb Hemost 2001; 7: 346-350.
54. Szolnoki Z, Somogyvári F, Kondacs A, Szabó M, Fodor L. Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke. J Neurol 2001; 248: 756-761.
55. Zunker P, Hohenstein C, Plendl HJ, Zeller JA, Caso V, Georgiadis D, Allardt A, Deuschl G. Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age. J Neurol 2001; 248: 701-704.
56. Streifer JY, Rosenberg N, Chetrit A, Eskaraev R, Sela BA, Dardik R, Zivelin A, Ravid B, Davidson J, Seligsohn U, Inbal A. Cerebrovascular events in patients with signifcant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism. Stroke 2001; 32: 2753-2758.
57. Grossmann R, Geisen U, Merati G, Müllges W, Schambeck CM, Walter U, Schwender S. Genetic risk factors in young adults with 'cryptogenic' ischemic cerebrovascular disease. Blood Coagul Fibrinolysis 2002; 13: 583-590.
58. Karttunen V, Alfthan G, Hiltunen L, Rasi V, Kervinen K, Kesaniemi YA, Hillbom M. Risk factors for cryptogenic ischaemic stroke. Eur J Neurol 2002; 9: 625-632.
59. Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefce G, Di Minno G. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002; 33: 51-56.
60. Szolnoki Z, Somogyvári F, Kondacs A, Szabó M, Fodor L. Evaluation of the interactions of common genetic mutations in stroke subtypes. J Neurol 2002; 249: 1391-1397.
61. Austin H, Chimowitz Mi, Hill HA, Chaturvedi S, Wechsler LR, Wityk RJ, Walz E, Wechsler JL, Coull B, Sila CA, Mitsias P, Evatt B, Hooper WC; Genetics and Stroke in the Young Study Group. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke 2002; 33: 2762-2768.
62. Karttunen V, Hiltunen L, Rasi V, Vahtera E, Hillbom M. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis 2003; 14: 261-268.
63. Lichy C, Reuner KH, Buggle F, Litfn F, Rickmann H, Kunze A, Brandt T, Grau A. Prothrombin G20210A mutation, but not factor V Leiden, is a risk factor in patients with persistent foramen ovale and otherwise unexplained cerebral ischemia. Cerebrovasc Dis 2003; 16: 83-87.
64. Petrovic D, Milanez T, Kobal J, Bregar D, Potisk KP, Peterlin B. Prothrombotic gene polymorphisms and atherothrom-botic cerebral infarction. Acta Neurol Scand 2003; 108: 109-113.
65. Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, Akkawi NM, Albertini A, Assanelli D, Vignolo LA, Padovani A. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 2003; 34: 28-33.
66. Szolnoki Z, Somogyvári F, Kondacs A, Szabó M, Fodor L, Bene J, Melegh B. Evaluation of the modifying efects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke. J Neurol Neurosurg Psychiatry 2003; 74: 1615-1620.
67. Aznar J, Mira Y, Vayá A, Corella D, Ferrando F, Villa P, Estellés A. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Tromb Haemost 2004; 91: 1031-1034.
68. Zee RYL, Cook NR, Cheng S, Reynolds R, Erlich HA, Lindpaintner K, Ridker PM. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet 2004; 13: 389-396.
69. Lichy C, Kropp S, Dong-Si T, Genius J, Dolan T, Hampe T, Stoll F, Reuner K, Grond-Ginsbach C, Grau A. A common polymorphism of the protein Z gene is associated with protein Z plasma levels and with risk of cerebral ischemia in the young. Stroke 2004; 35: 40-45.
70. Buyru N, Altinisik J, Somay G, Ulutin T. Factor V Leiden mutation in cerebrovascular disease. Clin Appl Tromb Hemost 2005; 11: 339-342.
71. Pezzini A, Grassi M, Del Zotto E, Archetti S, Spezi R, Vergani V, Assanelli D, Caimi L, Padovani A. Cumulative efect of predisposing genotypes and their interaction with modifable factors on the risk of ischemic stroke in young adults. Stroke 2005; 36: 533-539.
72. Rubattu S, Di Angelantonio E, Nitsch D, Gigante B, Zanda B, Stanzione R, Evangelista A, Pirisi A, Rosati G, Volpe M. Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Tromb Haemost 2005; 93: 1095-1100.
73. Lalouschek W, Schillinger M, Hsiek K, Endler G, Tentschert S, Lang W, Cheng S, Mannhalter C. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke 2005; 36: 1405-1409.
74. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Tromb Haemost 2005; 3: 1213-1217.
75. Lichy C, Dong-Si T, Reuner K, Genius J, Rickmann H, Hampe T, Dolan T, Stoll F, Grau A. Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fbrinolytic systems. J Neurol 2006; 253: 316-320.
76. de Paula Sabino A, Ribeiro DD, Carvalho MG, Cardoso J, Dusse LM, Fernandes AP. Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul Fibrinolysis 2006; 17: 271-275.
77. Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica 2006; 91: 844-847.
78. Berge E, Haug KB, Sandset EC, Haugbro KK, Turkovic M, Sandset PM. Te factor V Leiden, prothrombin gene 20210GA, methylenetetrahydrofolate reductase 677CT and platelet glycoprotein IIIa 1565TC mutations in patients with acute ischemic stroke and atrial fbrillation. Stroke 2007; 38: 1069-1071.
79. Lalouschek W, Endler G, Schillinger M, Hsieh K, Lang W, Cheng S, Bauer P, Wagner O, Mannhalter C. Candidate genetic risk factors of stroke: results of a multilocus genotyping assay. Clin Chem 2007; 53: 600-605.
80. Pezzini A, Grassi M, Iacoviello L, Del Zotto E, Archetti S, Giossi A, Padovani A. Inherited thrombophilia and stratifca-tion of ischaemic stroke risk among users of oral contraceptives. J Neurol Neurosurg Psychiatry 2007; 78: 271-276.
81. Berger K, Stögbauer F, Stoll M, Wellmann J, Huge A, Cheng S, Kessler C, John U, Assmann G, Ringelstein EB, Funke H. Te glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum Genet 2007; 121: 169-178.
82. Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 2007; 38: 2070-2073.
83. Voetch B, Jin RC, Bierl C, Benke KS, Kenet G, Simioni P, Ottaviano F, Damasceno BP, Annichini-Bizacchi JM, Handy SE, Loscalzo J. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke among young adults and children. Stroke 2007; 38: 41-49.
84. Le Cam-Duchez, Bagan-Triquenot A, Barbay V, Mihout B, Borg JY. Te G79A polymorphism of protein Z gene is an independent risk factor for cerebral venous thrombosis. J Neurol 2008; 255: 1521-1525.
85. Shi C, Kang X, Wang Y, Zhou Y. Te coagulation factor V Leiden, MTHFRC677T variant and eNOS 4ab polymorphism in young Chinese population with ischemic stroke. Clin Chim Acta 2008; 396: 7-9.
86. Pruissen DM, Rosendaal FR, Frijns CJM, Kappelle LJ, Vos HL, Algra A; Smart Study Group. Prothrombotic gene variation and new vascular events after cerebral ischemia of arterial origin. J Tromb Haemost 2008; 6: 1639-1644.
87. Celiker G, Can U, Verdi H, Yazici AC, Ozbek N, Atac FB. Prevalence of thrombophilic mutations and ACE I/D polymorphism in Turkish ischemic stroke patients. Clin Appl Tromb Hemost 2009; 15: 415-420.
88. Akar N, Yilmaz E, Akar E, Deda G, Sipahi T. Factor V (His1299Arg) in young Turkish patients with cerebral infarct. Haemostasis 2000; 30: 118-122.
89. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma pro-thrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
90. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F. Te heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Tromb Vasc Biol 1997; 17: 2418-2422.
91. Reuner KH, Ruf A, Grau A, Rickmann H, Stolz E, Jüttler E, Druschky KF, Patscheke H. Prothrombin gene G20210->A transition is a risk factor for cerebral venous thrombosis. Stroke 1998; 29: 1765-1769.
92. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
93. Egan RA, Kuyl JM, Press R, Lutsep HL. Lack of prothrombin gene mutation in young stroke patients. J Stroke Cerebrovasc Dis 2000; 9: 229-231.
94. Gomez Garcia EB, van Goor MP, Leebeek FW, Brouwers GJ, Koudstaal PJ, Dippel DW. Elevated prothrombin is a risk factor for cerebral arterial ischemia in young adults. Clin Neurol Neurosurg 2002; 104: 285-288.
95. Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Tromb Haemost 2002; 87: 614-621.
96. Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J, Ortín R, Tirado I, Souto JC, Fontcuberta J. Risk of ischemic stroke associated with functional thrombin-activatable fbrinolysis inhibitor plasma levels. Stroke 2003; 34: 2387-2391.
97. Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fbrinogen concentration. Lancet 1987; 2: 988-991.
98. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
99. Kannel WB, Wolf PA, Castelli WP, D'Agostino RP. Fibrinogen and risk of cardiovascular disease. Te Framingham Study. JAMA 1987; 258: 1183-1186.
100. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004; 35: 2300-2305.
101. Chen XC, Xu MT, Zhou W, Han CL, Chen WQ. A meta-analysis of relationship between β-fbrinogen gene-148C/T polymorphism and susceptibility to cerebral infarction in Han Chinese. Chin Med J (Engl) 2007; 120: 1198-1202.
102. Xu X, Li J, Sheng W, Liu L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis 2008; 26: 48-62.
103. Schmidt H, Schmidt R, Niederkorn K, Horner S, Becsagh P, Reinhart B, Schumacher M, Weinrauch V, Kostner GM. Beta-fbrinogen gene polymorphism (C148->T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler Tromb Vasc Biol 1998; 18: 487-492. (Pubitemid 28125645)
104. Yang ZG, Liu GX, Le FQ, Lin GX, Cheng S, Cai WW. Fibrinogen β-148 gene polymorphism associated with plasma fbrino-gen levels in ischemic stroke. Clin J Lab Diagn (Chin) 2001; 5: 12-14.
105. Blake GJ, Schmitz C, Lindpaintner K, Ridker PM. Mutation in the promoter region of the beta fbrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J 2001; 22: 2262-2266.
106. Liu R, Li JZ, Mu H, Jiang Y, Wang YL, Dang Q, Cui X, Ji M, Huang F. Te relationship of beta-fbrinogen gene polymorphisms and ischaemic cardiocerebral vascular disease. Zhonghua Xue Ye Xue Za Zhi 2002; 23: 453-456.
107. Cai YM, Gong WX, Ma SG, Chen H, Lin M, Sun HC. A study of single nucleotide polymorphisms in the 5' promoter region of B β fbrinogen gene and cerebral infarction. Chin J Hematol (Chin) 2003; 24: 488-489.
108. Zhang XH, Xu G, Zhao XY, Hou T, Zhang H. Study of fbrino-gen B β-148C/T gene polymorphism in patients with coronary heart disease and stroke. Chin J Emerg Med (Chin) 2003; 12: 683-685.
109. Zhao B, Lu B, Xing YQ, Xu ZE, Li JL, Chen XJ. Te beta fbrin-ogen gene-148C/T polymorphism and its association with plasma fbrinogen's function and level in cerebral infarction. Chin J Neurol (Chin) 2003; 36: 450-453.
110. Lv B, Zhao B, Xing YQ. Te study on the polymorphism of beta-fbrinogen gene-148C/T in the patients with cerebral infarction. Lin Chuang Shen Jing Bing Xue Za Zhi 2003; 16: 202-204.
111. Qian JJ, Liu CF, Zhao KR. Te study of fbrinogen gene-455G/A,-148C/T polymorphisms in patients with cerebral infarction. J Apoplexy Nervous Dis (Chin) 2004; 21: 147-149.
112. Li YJ, Huo Y, Gao XG. A statistical study on the relationship between gene polymorphisms of β-fbrinogen-148C/T, N5,N10-methylene tetrahydrofolic acid reductase 677C/T and cerebral infarction. Zhong Guo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi 2005; 12: 363-367.
113. Fu Y, Wei X, Ni PH, Ying YY, Song YY, Chen SD. Te relationship between the fve β-fbrinogen gene polymorphisms and cerebral infarction. Chin J Intern Med (Chin) 2005; 44: 914-917.
114. Pan XD, Ma AJ, Zou ZQ, Pei HZ, Li HF. Study of B fbrinogen gene-148C/T polymorphism and plasma fbrinogen levels in young patients with acute cerebral infarction. J Clin Neurol (Chin) 2005; 18: 40-42.
115. Song YQ, Zou HL, Song XJ, Wang W. Fibrinogen gene polymorphism-148C/T in patients with cerebral infarction. Cerebrovac Dis Foreign Med Sci (Chin) 2005; 13: 895-898.
116. van Goor ML, Gómez-Garcia EG, Leebeek F, Brouwers GJ, Koudstaal P, Dippel D. Te-148C/T fbrinogen gene polymorphism and fbrinogen levels in ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry 2005; 76: 121-123.
117. Wang SJ, Yuan XD, Gao J, Pei HZ, LI HF. Relation between fbrinogen polymorphisms and the type of cerebral infarction. Chin J Med Genet (Chin) 2005; 22: 572-574.
118. Xu F, Ni PH, Ying YH, Hu SQ. Fibrinogen B β gene-148C/T polymorphism in stroke. J Diagn Concepts Pract (Chin) 2005; 4: 38-40.
119. Gao X, Yang H, ZhiPing T. Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. Neurosci Lett 2006; 398: 172-177.
120. Ma AJ, Pan XD, Zhang CS, Xing Y, Zhang YN. A linkage between beta-fbrinogen gene-148C/T polymorphism and cerebral infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006; 23: 202-204.
121. Liang L, Sun C, Liao XP. Liang L, Sun C, Liao XP, Xiao F, Chen XD, Huang SX, Tang XL, Wen GQ, Long ZG, Wang XY, Liu GX, Cheng S, Cai WW. Analysis of the relationship between α-and β-fbrinogen gene haplotypes and nucle-otide polymorphisms associated with ischemic stroke in the Hainan Han population. Zhong Hua Yi Xue Yi Chuan Xue Za Zhi 2006; 23: 316-319.
122. Chen XC, Xu MT, Zhou W, Han CL, Chen WQ. A meta-analysis of beta-fbrinogen gene-455G/A polymorphism and plasma fbrinogen level in Chinese cerebral infarction patients. Biomed Environ Sci 2007; 20: 366-372.
123. Kessler C, Spitzer C, Stauske D, Mende S, Stadlmüller J, Walther R, Rettig R. Te apolipoprotein E and beta-fbrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Tromb Vasc Biol 1997; 17: 2880-2884.
124. Nishiuma S, Kario K, Yakushijin K, Maeda M, Murai R, Matsuo T, Ikeda U, Shimada K, Matsuo M. Genetic variation in the promoter region of the beta-fbrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis 1998; 9: 373-379.
125. Liu Y, Pan JQ, Wang SJ. Beta-fbrinogen gene-455A/G polymorphism and plasma fbrinogen level in Chinese stroke patients. Zhong Hua Yi Xue Za Zhi 2000; 8: 336-338.
126. Li FQ, Liu GX, Yang ZG. Efect of β-fbrinogen-455G/A gene polymorphism on plasma fbrinogen levels in patients with ischemic stroke. Zhong Guo Shi Yan Xue Ye Xue Za Zhi 2001; 9: 165-168.
127. Ma LY, Zhao Y, Wang XY. Association of fbrinogen gene-455G/A polymorphism with ischemic stroke. Zhong Hua Lao Nian Xin Nao Xue Guan Bing Za Zhi 2001; 3: 96-98.
128. Zheng H, Xing YQ, Zhao B. Association of β-fbrinogen gene-455G/A polymorphism and plasma fbrinogen level with acute cerebral thrombosis. Zhong Hua Xue Ye Xue Za Zhi 2001; 22: 151-152.
129. Zhou SN, Pan M, Ma YY. Te association between β Hae polymorphism located in the promoter region of β-fbrinogen gene, plasma fbrinogen levels and cerebral infarction. Nao Yu Shen Jing Ji Bing Za Zhi 2002; 10: 13-16.
130. Bi S, Wang DS, Li GL. Relationship between β-fbrinogen promoter-455G/A (Hae) polymorphism and plasma fbrinogen of the patients with ischemic cerebrovascular disease. Zhong Hua Shen Jing Yi Xue Za Zhi 2003; 2: 252-256.
131. Dong QL, Yhang C. Association between the polymorphism of beta-fbrinogen gene-455G/A and ischemic stroke. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004; 21: 274-276.
132. Sun H, Lu FH, Tian Q, Wen PE, Wu F, Wang X. Te association of β-fbrinogen-455G/A gene polymorphism with essential hypertension in the elderly. Chin J Geriatr 2004; 23: 365-369.
133. Fu Q, Xing HY, Liao XP. Single nucleotide polymorphisms-455G/A,-854G/A, and-1420G/A in β-fbrinogen gene and their association with ischemic stroke. Zhong Hua Shen Jing Yi Xue Za Zhi 2005; 38: 565-569.
134. Zhao WJ, Yang HP, Shen YF. Relationship of fbrinogen and hemorheological changes with beta-fbrinogen gene-455G/A polymorphism in patients with cerebral infarction. Zhong Guo Lin Chuang Kang Fu 2005; 9: 94-96.
135. Yamada Y, Metoki N, Yoshida H, Satoh K, Ichihara S, Kato K, Kameyama T, Yokoi K, Matsuo H, Segawa T, Watanabe S, Nozawa Y. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Tromb Vasc Biol 2006; 26: 1920-1925.
136. Xing HY, Liao XP, Xiao F. Haplotypes in the promoter region of β-fbrinogen gene and their relationship with ischemic stroke in the Han population in Hainan. Guo Ji Yi Chuan Xue Za Zhi 2006; 29: 328-335.
137. Zhou J, Li XX. Association of β-fbrinogen gene-455G/A polymorphism with cerebral infarction. Shen Jing Sun Shang Yu Gong Neng Chong Jian 2006; 1: 149-150, 160.
138. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specifc associations of the fbrinogen B beta 448 polymorphism, fbrinogen levels, and acute cerebrovascular disease. Arterioscler Tromb Vasc Biol 1997; 17: 589-594.
139. Carter AM, Catto AJ, Grant PJ. Association of the alpha-fbrinogen Tr312Ala polymorphism with poststroke mortality in subject with atrial fbrillation. Circulation 1999; 99: 2423-2426.
140. Green F, Kelleher C, Wilkes H, Temple A, Maede T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Tromb 1991; 11: 540-546.
141. Maguire JM, Takkinstian A, Sturm J, Levi C, Lincz L, Parsons M, Whyte S, Attia J. Polymorphisms in platelet glyco-protein 1balpha and factor VII and risk of ischemic stroke: a meta-analysis. Stroke 2008; 39: 1710-1716.
142. Heywood DM, Carter AM, Catto AJ, Bamford JM, Grant PJ. Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and post-stroke mortality. Stroke 1997; 28: 816-821.
143. Nishiuma S, Kario K, Nakanishi K, Yakushijin K, Kageyama G, Matsunaka T, Matsuo T, Kanai N, Ikeda U, Shimada K, Matsuo M. Factor VII R353Q polymorphism and lacunar stroke in Japanese hypertensive patients and normotensive controls. Blood Coagul Fibrinolysis 1997; 8: 525-530.
144. Corral J, González-Conejero R, Lozano ML, Rivera J, Vicente V. Genetic polymorphisms of factor VII are not associated with arterial thrombosis. Blood Coagul Fibrinolysis 1998; 9: 267-272.
145. Kain K, Catto AJ, Young J, Bamford J, Bavington J, Grant PJ. Coagulation factor VII activity, Arg/Gln353 polymorphism and features of insulin resistance in frst-degree relatives of South Asian patients with stroke. Tromb Haemost 2002; 88: 954-960.
146. Kang WY, Wang HL, Xiong LF, Wang X F, Chu HY, Qu B, Liu XF, Yin J, Duan BH, Wang ZY. Polymorphisms of the coagulation factor VII gene and its plasma levels in relation to acute cerebral infarction diferences in allelic frequencies between Chinese Han and European populations. Chin Med J (Engl) 2004; 117: 71-74.
147. Yeh PS, Lin HJ, Li YH, Lin KC, Cheng TJ, Chang CY, Ke DS. Prognosis of
148. Funk M, Endler G, Lalouschek W, Hsich K, Schillinger M, Lang W, Mannhalter C. Factor VII gene haplotypes and risk of ischemic stroke. Clin Chem 2006; 52: 1190-1192.
149. Ariëns RAS, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fbrin clot formation and efects of genetic polymorphisms. Blood 2002; 100: 743-754.
150. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813-816.
151. Corral J, González-Conejero R, Iniesta JA, Riviera J, Martínez C, Vicente V. Te FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-297.
152. Elbaz A, Poirier O, Canaple S, Chédru F, Cambien F, Amarenco P. Te association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-591.
153. Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R, Moretti M, Scapoli GL. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol 2001; 67: 183-188.
154. Reiner AP, Frank MB, Schwartz SM, Linenberger ML, Longstreth W T, Teramura G, Rosendaal FR, Psaty BM, Siscovick DS. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol 2002; 116: 376-382.
155. Endler G, Funk M, Haering D, Lalouschek W, Lang W, Mirafzal M, Wagner O, Mannhalter C. Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease? Br J Haematol 2003; 120: 310-314.
156. Slowik A, Dziedzic T, Pera J, Figlewicz DA, Szczudlik A. Coagulation factor XIII VaI34Leu polymorphism in patients with small vessel disease or primary intracerebral hemorrhage. Cerebrovasc Dis 2005; 19: 165-170.
157. Van der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, van der Kuip DA, Hofman A, Witteman JC, Gomez Garcia EB. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 2004; 124: 343-347.
158. Lacquemant C, Gaucher C, Delorme C, Chatellier G, Galois Y, Rodier M, Passa P, Balkau B, Mazurier C, Marre M, Froguel P. Association between high von Willebrand factor levels and the Tr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. Te GENEDIAB Study Group and the DESIR Study Group. Kidney Int 2000; 57:1437-1443.
159. Dai K, Gao W, Ruan C. Te Sma I polymorphism in the von Willebrand factor gene associated with acute ischemic stroke. Tromb Res 2001; 104: 389-395.
160. Gao W, Dai L, Su J, Wang Z, Ruan C. Te frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial throm-botic disorders. Tromb Haemost 2004; 91: 1257-1258.
161. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez Garcia EB, Dippel DW, Leebeek FW. High von Willebrand factor levels increase the risk of frst ischemic stroke: infuence of ADAMTS13, infammation, and genetic variability. Stroke 2006; 37: 2672-2677.
162. Oguchi S, Ito D, Murata M, Yoshida T, Tanahashi N, Fukuuchi Y, Ikeda Y, Watanabe K. Genotype distribution of the 46C/T polymorphism of coagulation factor XII in the Japanese population: absence of its association with ischemic cerebrovascular disease. Tromb Haemost 2000; 83: 178-179.
163. Santamaría A, Mateo J, Tirado I, Oliver A, Belvís R, Martí-Fábregas J, Felices R, Soria JM, Souto JC, Fontcuberta J. Homozygosity of the T allele of the 46 C>T polymorphism in the F12 gene is a risk factor for ischemic stroke in the Spanish population. Stroke 2004; 35: 1795-1799. (Pubitemid 38971853)
164. Reuner KH, Jenetzky E, Aleu A, Litfn F, Mellado P, Kloss M, Jüttler E, Grau AJ, Rickmann H, Patscheke H, Lichy C. Factor XII C46T gene polymorphism and the risk of cerebral venous thrombosis. Neurology 2008; 70: 129-132.
165. Attia J, Takkinstian A, Wang Y, Lincz L, Parsons M, Sturm J, McGettigan P, Scott R, Meldrum C, Levi C. Te PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. J Stroke Cerebrovasc Dis 2007; 16: 173-179.
166. Ariyaratnam R, Casas J P, Whittaker J, Smeeth L, Hingorani AD, Sharma P. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 Individuals. PLoS Med 2007; 4: e131.
167. Rao R, Tah V, Casas JP, Hingorani A, Whittaker J, Smeeth L, Sharma P. Ischaemic stroke subtypes and their genetic basis: a comprehensive meta-analysis of small and large vessel stroke. Eur Neurol 2009; 61: 76-86.
168. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cer-ebrovascular disease. Tromb Haemost 1997; 77: 730-734.
169. Jeppesen LL, Wilhelmsen K, Nielsen LB, Jørgensen HS, Nakayama H, Raaschou HO, Nielsen JD, Olsen TS, Winther K. An insertion/deletion polymorphism in the promoter region of the plasminogen activator inhibitor-1 gene is associated with plasma levels but not with stroke risk in the elderly. J Stroke Cerebrovasc Dis 1998; 7: 385-390.
170. Liu S, Yang L, Wang X. Te study of the plasma PAI-1 activity and its promoter region gene polymorphism in acute cerebral infarction. Zhonghua Shen Jing Ge Za Zhi 1998; 31: 264-266.
171. Heijmans BT, Westendorp RGJ, Knook DL, Kluft C, Slagboom PE. Angiotensin I-converting enzyme and plas-minogen activator inhibitor-1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort. J Am Coll Cardiol 1999; 34: 1176-1183.
172. Endler G, Lalouschek W, Exner M, Mitterbauer G, Häring D, Mannhalter C. Te 4G/4G genotype at nucleotide position-675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 2000; 110: 469-471.
173. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, Grobbee DE. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000; 101: 67-70.
174. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the plasminogen activator inhibi-tor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001; 11: 294-299.
175. Elbaz A, Cambien F, Amarenco P; GÉNIC Investigators. Plasminogen activator inhibitor genotype and brain infarction. Circulation 2001; 103: e13-e14.
176. Zhang C. Li J, Li L, Luo B. Te study of PAI-1 promoter region gene polymorphism in cerebrovascular disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2001; 18: 383-387. (Pubitemid 32971169)
177. Sun Q, Zhang YD, Liu Y. Te study of plasma PAI-1 activity and its gene polymorphism in cerebral infarction. Nao Yu Shen Jing Ji Bing Za Zhi 2001; 9: 323-326.
178. Zhang YD, Sun Q, Liu Y. Te association of PAI-1 gene polymorphism with cerebral infarction and recurrent cerebral infarction. Lin Chuang Shen Jing Bing Xue Za Zhi 2001; 14: 262-265.
179. Hindorf LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP. Te association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocar-dial infarction and stroke in young women. J Cardiovasc Risk 2002; 9: 131-137.
180. Kain K, Young J, Bamford J, Bavington J, Grant PJ, Catto AJ. Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke. Cerebrovasc Dis 2002; 14: 77-83.
181. Chen CH, Eng HL, Chang CJ, Tsai TT, Lai ML, Chen HY, Liu CJ, Lin TM. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profles, and ischemic stroke. J Lab Clin Med 2003; 142: 100-105.
182. Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, Sharrett AR, Tracy RP. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Tromb Haemost 2003; 1: 1799-1804.
183. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 2003; 34: 2822-2828.
184. Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J (Engl) 2003; 116: 1707-1710.
185. Zhang AJ, Song BH, Wang JX. Te association of PAI-1 4G/5G polymorphism with cerebral infarction. Shan Dong Yi Yao 2003; 43: 42-43.
186. Guan LX, Wang JX, Wang JX. Efect of gene polymorphism of the PAI-1 gene promoter region on patients with essential hypertension complicated by cerebral infarction. Zhong Hua Lao Nian Yi Xue Za Zhi 2004; 23: 765-768.
187. Yi GH. A study of the plasma plasminogen activator inhibi-tor-1 activity and its promoter region gene polymorphism in acute cerebral infarction. Qing Dao Da Xue Yi Xue Yuan Xue Bao 2004; 40: 229-231.
188. Jood K, Ladenvall P, Tjärnlund A, Ladenvail C, Andersson M, Nilsson S, Blomstrand C, Jern C. Fibrinolytic gene polymorphism and ischemic stroke. Stroke 2005; 36: 2077-2081.
189. van Goor ML, Garcia EG, Leebeek F, Brouwers GJ, Koudstaal P, Dippel D. Te plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke: a case-control study. Tromb Haemost 2005; 93: 92-96.
190. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated fndings in two nested case-control studies based on independent cohorts. Stroke 2005; 36: 1661-1665.
191. Boncoraglio GB, Bodini A, Brambilla C, Carriero MR, Ciusani E, Parati EA. An efect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conficting associations with myocardial infarction and stroke. Cerebrovasc Dis 2006; 22: 191-195.
192. Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, Rodondi N, Li R, Zmuda JM, Harris TB. Plasminogen activator inhibitor type 1 gene polymorphisms and haplo-types are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 2006; 152: 1109-1115.
193. Xu B, Zhang CY, Xian BX: A study of the plasma plasminogen activator inhibitor-1 activity and its promoter region 4G/5G gene polymorphism in acute cerebral infarction. Zhong Guo Yi Shi Jin Xiu Za Zhi 2006; 29: 26-28.
194. Lichy C, Kloss M, Reismann P, Genius J, Grau A, Reuner K. No evidence for plasminogen activator inhibitor 1 4G/4G genotype as risk factor for cerebral venous thrombosis. J Neurol 2007; 254: 1124-1125.
195. Saidi S, Slamia LB, Mahjoub T, Ammou SB, Almawi WY. Association of PAI-1 4G/5G and-841G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study. J Stroke Cerebrovasc Dis 2007; 16: 153-159.
196. Jannes J, Hamilton-Bruce MA, Pilotto L, Smith BJ, Mullighan CG, Bardy PG, Koblar SA. Tissue plasminogen activator-7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke 2004; 35: 1090-1094.
197. Armstrong CA, Bevan SN, Gormley KT, Markus HS, Koblar SA. Tissue plasminogen activator-7351C/T polymorphism and lacunar stroke. Stroke 2006; 37: 329-330.
198. Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC. High functional levels of thrombin-activatable fbrinolysis inhibitor are associated with an increased risk of frst ischemic stroke. J Tromb Haemost 2005; 3: 2211-2218.
199. Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C. Trombin activatable fbrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Tromb Vasc Biol 2007; 27: 955-962.
200. Biswas A, Tiwari AK, Ranjan R, Meena A, Akhter MS, Yadav BK, Behari M, Saxena R. Prothrombotic polymorphisms, mutations, and their association with pediatric non-cardioembolic stroke in Asian-Indian patients. Ann Hematol 2009; 88: 473-478.
201. Fernandez-Cardenas, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J. Infuence of thrombin-activatable fbrinolysis inhibitor and plasmino-gen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Tromb Haemost 2007; 5: 1862-1868.
202. Weiler H. Mouse models of thrombosis: thrombomodulin. Tromb Haemost 2004; 92: 467-477. (Pubitemid 39248003)
203. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I; PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Circulation 2004; 109: 1343-1348.
204. Schumacher A, Seljefot I, Sommervoll L, Christensen B, Otterstad JE, Arnesen H. Increased levels of endothelial haemostatic markers in patients with coronary heart disease. Tromb Res 2002; 105: 25-31. (Pubitemid 34182832)
205. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Trombomodulin gene mutations associated with myocar-dial infarction. Circulation 1997; 96:15-18.
206. Wu KK, Aleksic N, Ahn C, Boerwinkle E, Folsom AR, Juneja H; Atherosclerosis Risk in Communities Study (ARIC) Investigators. Trombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation 2001; 103: 1386-1389. (Pubitemid 32220629)
207. Cole JW, Roberts SC, Gallagher M, Giles WH, Mitchell BD, Steinberg KK, Wozniak MA,Macko R F, Reinhart LJ, Kittner SJ; Stroke Prevention in Young Women Study. Trombomodulin Ala455Val polymorphism and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study. BMC Neurol 2004; 4: 21.
208. Auro K, Komulainen K, Alanne M, Silander K, Peltonen L, Perola M, Salomaa V. Trombomodulin gene polymorphisms and haplotypes and the risk of cardiovascular events: a prospective follow-up study. Arterioscler Tromb Vasc Biol 2006; 26: 942-947.
209. Olivot JM, Labreuche J, De Broucker T, Poirier O, Cambien F, Aiach M, Amarenco P; GENIC Investigators. Trombomodulin gene polymorphisms in brain infarction and mortality after stroke. J Neurol 2008; 255: 514-519.
210. Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fbrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 1997; 28: 1392-1395.
211. Carter AM, Catto AJ, Bamford JM, Grant PJ. Association of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke. Stroke 1999; 30: 2606-2611.
212. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT Jr, Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000; 31: 1628-1633.
213. Saidi S, Mahjoub T, Slamia LB, Ammou SB, Al-Subaie AM, Almawi WY. Polymorphisms of the human platelet alloanti-gens HPA-1, HPA-2, HPA-3, and HPA-4 in ischemic stroke. Am J Hematol 2008; 83: 570-573.
214. Saidi S, Mahjoub T, Slamia LB, Ammou SB, Al-Subaie AM, Almawi WY. Association of human platelet alloantigen 1 through 5 polymorphism with ischemic stroke. Cerebrovasc Dis 2008; 25: 81-86. (Pubitemid 351280379)
215. Corral J, González-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis-role of HPA-1b polymorphism in platelet function. Blood Coagul Fibrinolysis 1997; 8: 284-290.
216. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glyco-protein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-388.
217. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Tromb Vasc Biol 1998; 18: 1124-1131.
218. Wagner KR et al. Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke Prevention in Young Women Study. Stroke 1998; 29: 581-585.
219. Kekomäki S, Hämäläinen L, Kauppinen-Mäkelin R, Palomäki H, Kaste M, Kontula K. Genetic polymorphism of platelet glycoprotein IIIa in patients with acute myocardial infarction and acute ischaemic stroke. J Cardiovasc Risk 1999; 6: 13-17.
220. Meiklejohn DJ, Vickers MA, Morrison ER, Dijkhuisen R, Moore I, Urbaniak SJ, Greaves M. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001; 112: 621-631.
221. van Goor ML, Gómez Garcia E, Brouwers GJ, Leebeek FW, Koudstaal PJ, Dippel DW. PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke. Tromb Res 2002; 108: 63-65.
222. Szolnoki Z, Somogyvári F, Kondacs A, Szabó M, Bene J, Havasi V, Komlósi K, Melegh B. Increased prevalence of platelet glycoprotein IIb/IIIa PLA2 allele in ischaemic stroke associated with large vessel pathology. Tromb Res 2003; 109: 265-269.
223. Chen CH, Lo YK, Ke D, Liu CK, Liou CW, Wu HL, Lai ML; Southern Taiwan Young Stroke Study Group. Platelet glyco-protein Ia C807T, Ib C3550T, and IIIa Pl(A1/A2) polymorphisms and ischemic stroke in young Taiwanese. J Neurol Sci 2004; 227: 1-5.
224. Slowik A, Dziedzic T, Turaj W, Pera J, Glodzik-Sobanska L, Szermer P, Malecki MT, Figlewicz DA, Szczudlik A. A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke 2004; 35: 1589-1593.
225. Nádasi E, Bene J, Havasi V, Komlósi K, Talián G, Melegh G, Papp E, Gasztonyi B, Szolnoki Z, Sandor J, Mózsik G, Tóth K, Melegh B, Wittmann I. Detection of the Leu40Arg variant of the platelet glycoprotein IIb/IIIa receptor in subjects with thrombotic diseases. Tromb Res 2005; 116: 479-482.
226. Lanni F, Santulli G, Izzo R, Rubattu S, Zanda B, Volpe M, Iaccarino G, Trimarco B. Te Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens 2007; 25: 551-556.
227. Oksala NK, Heikkinen M, Mikkelsson J, Pohjasvaara T, Kaste M, Erkinjuntti T, Karhunen PJ. Smoking and the platelet fbrinogen receptor glycoprotein IIb/IIIA PlA1/A2 polymorphism interact in the risk of lacunar stroke and midterm survival. Stroke 2007; 38: 50-55.
228. Zhang Y, Wang Y, Wang Y, Cui C, Huang P, Li X, Liu S, Lendon C, Guo N. Platelet glycoprotein polymorphisms: risk, in vivo expression and severity of atherothrombotic stroke in Chinese. Clin Chim Acta 2007; 378: 99-104.
229. Nikolopoulos GK, Tsantes AE, Bagos PG, Travlou A, Vaiopoulos G. Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: a meta-analysis. Tromb Res 2007; 119: 501-510.
230. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. Te α2 gene coding sequence T807/A873 of the platelet collagen receptor inttegrin α2β1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999; 93: 3583-3586.
231. Corral J, González-Conejero R, Rivera J, Ortuño F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and func-tion-efect in thromboembolic diseases. Tromb Haemost 1999; 81: 951-956.
232. Cole VJ, Staton JM, Eikelboom JW, Hankey GJ, Shen Y, Berndt MC, Baker RI. Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. J Tromb Haemost 2003; 1: 963-970.
233. De Oliveira MH, André C, Spector N, Luiz RR, de Castro Souza G, Gadelha T. 807C/T polymorphism in the platelet glycoprotein Ia gene in young patients with ischemic stroke of undetermined etiology. Blood Coagul Fibrinolysis 2007; 18: 599-602.
234. Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial throm-botic disease. Blood 1998; 92: 2771-2776.
235. Corral J, Lozano ML, Gonzalez-Conejero R, Martinez C, Iniesta JA, Rivera J, Vicente V. A common polymorphism fanking the ATG initiator codon of GPIbα does not afect expression and is not a major risk factor for arterial thrombosis. Tromb Haemost 2000; 83: 23-28.
236. Sonoda A, Murata M, Ito D, Tanahashi N, Ohta A, Tada Y, Takeshita E, Yoshida T, Saito I, Yamamoto M, Ikeda Y, Fukuuchi Y, Watanabe K. Association between platelet glyco-protein Ibalpha genotype and ischemic cerebrovascular disease. Stroke 2000; 31: 493-497.
237. Chen F, Jian Z, Xie Q, Pu X, Xiao B, Han L. Polymorphism of human platelet alloantigen in Chinese patients with acute myocardial infarction and acute ischemic stroke. Chin Med J (Engl) 2000; 113: 702-705.
238. Sonoda A, Murata M, Ikeda Y, Fukuuchi Y, Watanabe K. Stroke and platelet glycoprotein Ibalpha polymorphisms. Tromb Haemost 2001; 85: 573-574.
239. Baker RI, Eikelboom J, Lofthouse E, Staples N, Afshar-Kharghan V, López JA, Shen Y, Berndt MC, Hankey G. Platelet glycoprotein Ibα Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood 2001; 98: 36-40.
240. Frank MB, Reiner AP, Schwartz SM, Kumar PN, Pearce RM, Arbogast PG, Longstreth WT Jr, Rosendaal FR, Psaty BM, Siscovick DS. Te Kozak sequence polymorphism of platelet glycoprotein Ibα and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood 2001; 97: 875-879.
241. Hsieh K, Funk M, Schillinger M, Endler G, Janisiw M, Reisinger M, Unger P, Greisenegger S, Lang W, Lalouschek W, Mannhalter C. Vienna Stroke Registry. Impact of the platelet glycoprotein Ib alpha Kozak polymorphism on the risk of ischemic cerebrovascular events: a case-control study. Blood Coagul Fibrinolysis 2004; 15: 469-473.
242. Ishii K, Murata M, Oguchi S, Takeshita E, Ito D, Tanahashi N, Fukuuchi Y, Saitou I, Ikeda Y, Watanabe K. Genetic risk factors for ischemic cerebrovascular disease-analysis on ffteen candidate prothrombotic gene polymorphisms in the Japanese population. Rinsho Byori 2004; 52: 22-27.
243. Gao XG, Huo Y, Liu XZ, Teng Z P. Gene polymorphism of platelet glycoprotein Ibalpha in Chinese patients with large-and small-artery subtypes of ischemic stroke. Eur Neurol 2005; 54: 73-77.
244. Kemkes-Matthes B, Matthes KJ. Protein Z. Semin Tromb Hemost 2001; 27: 551-556.
245. Broze GJ Jr. Protein-Z and thrombosis. Lancet 2001; 357: 900-901.
246. Staton J, Sayer M, Hankey GJ, Cole V, Tom J, Eikelboom JW. Protein Z gene polymorphisms, protein Z concentrations, and ischemic stroke. Stroke 2005; 36: 1123-1127.
247. Obach V, Muñoz X, Sala N, Garcia de Frutos P, Chamorro A. Intronic c.573 + 79G>A polymorphism of protein Z gene in haemorrhagic and ischaemic stroke. Tromb Haemost 2006; 95: 1040-1041.
248. van Goor MP, Dippel DW, Jie KS, de Maat MP, Koudstaal PJ, Leebeek FW. Low protein Z levels but not the protein Z gene G79A polymorphism are a risk factor for ischemic stroke. Tromb Res 2008; 123: 213-218.
249. Van Heerde WL, de Groot PG, Reutelingsperger C. Te complexity of the phospholipids binding protein annexin V. Tromb Haemost 1995; 73: 172-179.
250. Cookson BT, Engelhardt S, Smith C, Bamford HA, Prochazka M, Tait JF. Organization of the human annexin V (ANX5) gene. Genomics 1994; 20: 463-467.
251. González-Conejero R, Corral J, Roldán V, Martinez C, Marin F, Rivera J, Iniesta JA, Lozano M, Marco P, Vicente V. A common polymorphism in the annexin V Kozak sequence (-1C/T) increases translation efciency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood 2002; 100: 2081-2086.
252. Van Goor M-LPJ, van Heerde WL, Schoormans S, Dippel DWJ, Leebeek FWG. Te annexin A5-1C/T polymorphism in ischemic stroke: a case-control study. J Tromb Haemost 2005; 3: 173-175.
253. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis. Te role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
254. Ratnof OD. Activation of Hageman factor by L-homocysteine. Science 1968; 162: 1007-1009.
255. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a throm-botic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-1386.
256. Barbato JC, Catanescu O, Murray K, DiBello PM, Jacobsen DW. Targeting of metallothionein by L-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler Tromb Vasc Biol 2007; 27: 49-54.
257. Colgan SM, Austin RC. Homocysteinylation of metal-lothionein impaires intracellular redox homeostasis: the enemy within! Arterioscler Tromb Vasc Biol 2007; 27: 8-11.
258. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969; 56: 111-128.
259. Frosst P, Blom HJ, Milos R,Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylentetrahy-drofolate reductase. Nat Genet 1995; 10: 111-113.
260. Kang SS, Wong PW, Susmano J, Sora J, Norusis M, Ruggie N. Termolabile methylentetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-545.
261. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silvera S, Plomaritoglou A, Furie KL. Homocysteine, MTHFR 677C/T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59: 529-536.
262. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005; 365: 224-232.
263. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke 2005; 36: 1581-1587.
264. Banerjee I, Veena Gupta V, Ganesh S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: a meta-analysis. J Hum Genet 2007; 52: 205-219.
265. Duca F, Sacchi E, Tagliabue L, Tajoli E. C677T methylene-tetrahydrofolate reductase (MTHFR) mutation in stroke [abstract]. Tromb Haemost 1997; 78(Suppl): S102.
266. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahy-drofolate reductase gene, homocysteine, and ischemic cer-ebrovascular disease. Stroke 1997; 28: 1739-1743.
267. Kostulas K, Crisby M, Huang WX, Lannfelt L, Hagenfeldt L, Eggertsen G, Kostulas V, Hillert J. A methylenetetrahydro-folate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. Eur J Clin Invest 1998; 28: 285-289.
268. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Kitamura K, Yazaki Y. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Tromb Vasc Biol 1998; 18: 1465-1469.
269. Nakata Y, Katsuya T, Takami S, Sato N, Fu Y, Ishikawa K, Takiuchi S, Rakugi H, Miki T, Higaki J, Ogihara T. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens 1998; 11: 1019-1023.
270. Reuner KH, Ruf A, Kaps M, Druschky KF, Patscheke H. Te mutation C677→T in the methylene tetrahydrofolate reduct-ase gene and stroke. Tromb Haemost 1998; 79: 450-451.
271. Salooja N, Catto A, Carter A, Tudenham EG, Grant PJ. Methylene tetrahydrofolate reductase C677T genotype and stroke. Clin Lab Haematol 1998; 20: 357-361.
272. Soriente L, Coppola A, Madonna P, Cerbone AM, Di Minno G, Orefce G, D'Angelo A. Homozygous C677T mutation of the 5, 10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke 1998; 29: 869-871.
273. Harmon DL, Doyle RM, Meleady R, Doyle M, Shields DC, Barry R, Coakley D, Graham IM, Whitehead AS. Genetic analysis of the thermolabile variant of 5, 10-methylenetet-rahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Tromb Vasc Biol 1999; 19: 208-211.
274. Kristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Dahlén G, Olsson T. Hyperhomocysteinemia and hypofbri-nolysis in young adults with ischemic stroke. Stroke 1999; 30: 974-980.
275. Lalouschek W, Aull S, Serles W, Schnider P, Mannhalter C, Lang T, Deecke L, Zeiler K. Genetic and nongenetic factors infuencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. J Lab Clin Med 1999; 133: 575-582.
276. Notsu Y, Nabika T, Park HY, Masuda J, Kobayashi S. Evaluation of genetic risk factors for silent brain infarction. Stroke 1999; 30: 1881-1886.
277. Press RD, Beamer N, Evans A, DeLoughery TG, Coull BM. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. Diagn Mol Pathol 1999; 8: 54-58.
278. Bova I, Chapman J, Sylantiev C, Korczyn AD, Bornstein NM. Te A677V methylenetetrahydrofolate reductase gene polymorphism and carotid atherosclerosis. Stroke 1999; 30: 2180-2182.
279. Gaustadnes M, Rüdiger N, Møller J, Rasmussen K, Bjerregaard Larsen T, Ingerslev J. Trombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis 1999; 10: 251-259.
280. Teng L, Zhao YB, Wang XC. Relation between MTHFR gene polymorphism and arteriosclerotic cerebral infarction. Yi Chuan 1999; 21: 13-16.
281. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocysteine and ischemic stroke due to large-and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31: 1069-1075.
282. Gross B, Antebi A, Cassel A, Honigman S. Is a mutation in the enzyme MTHFR a risk factor for stroke in young adults [abstract]? Neurology 2000; 54(Suppl 3): A142.
283. Yoo JH, Choi GD, Kang SS.Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia. Arterioscler Tromb Vasc Biol 2000; 20: 1921-1925.
284. Zheng YZ, Tong J, Do XP, Pu XQ, Zhou BT.Prevalence of meth-ylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol 2000; 109: 870-874.
285. Dai C, Zhang G. Study on homocysteine metabolism related enzymes gene mutations in Chinese patients with ischemic cardiovascular and cerebrovascular disease. Zhonghua Xue Ye Xue Za Zhi 2001; 22: 484-487.
286. Topic E, Šimundic AM, Štefanovic M, Demarin V, Vukovic V, Lovrencic-Huzjan A, untar I. Polymorphism of apoprotein E (APOE), methylenetetrahydrofolte reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. Clin Chem Lab Med 2001; 39: 346-350.
287. Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J Med Sci 2001; 47: 255-262.
288. Zhang G, Dai C.Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlu-sive coronary artery or cerebral vascular diseases. Tromb Res 2001; 104: 187-195.
289. Gallai V, Caso V, Paciaroni M, Cardaioli G, Arning E, Bottiglieri T, Parnetti L. Mild hyperhomocyt(e)inemia: a possible risk factor for cervical artery dissection. Stroke 2001; 32: 714-718.
290. Zhang YD, Zhu ZG, Liu Y. Te association of plasma Hcy level and MTHFR gene polymorphism with cerebral infarction. Zhong Feng Yu Shen Jing Ji Bing Za Zhi 2001; 18: 198-200.
291. Huang Y, Zhao YY, Li S. Hyperhomocysteine, methylene-tetrahydrofolate reductase gene, and other risk factors in ischemic stroke. Zhonghua Yi Xue Za Zhi 2002; 82: 119-122.
292. Li C, Zhang C, Qiu S, Lu X, Zeng Y, Wu H, Chen W, Luo W, Liu J. Polymorphisms of ACE-1 and MTHFR genes and genetic susceptibility of ischemic stroke. Zhonghua Yi Xue Za Zhi 2002; 82: 1046-1049.
293. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetet-rahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002; 33: 2351-2356.
294. Pezzini A, Del Zotto E, Archetti S, Negrini R, Bani P, Albertini A, Grassi M, Assanelli D, Gasparotti R, Vignolo LA, Magoni M, Padovani A. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke 2002; 33: 664-669.
295. Yingdong Z, Zhigang Z, Yang L. Association of plasma homocysteine level and N5, N10-methylenetetrahydrofolate reductase gene polymorphism with cerebral infarction. Chin Med Sci J 2002; 17: 231-235.
296. Tu CQ, Huang MQ, Wu JZ. Te relation of methylenetetrahy-drofolate reductase gene mutation and cystathionine β-syn-thase gene mutation exist in cerebral infarction. Xue Shuan Yu Zhi Xue Xue 2002; 8: 149-151.
297. Choi BO, Kim NK, Kim SH, Kang MS, Lee S, Ahn JY, Kim OJ, Kim S, Oh D. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. Tromb Res 2003; 111: 39-44.
298. Kelly PJ, Shih VE, Kistler JP, Barron M, Lee H, Mandell R, Furie KL. Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortifcation. Stroke 2003; 34: e51-e54.
299. Kim NK, Choi BO, Jung WS, Choi YJ, Choi KG. Hyperhomocysteinemia as an independent risk factor for silent brain infarction. Neurology 2003; 61: 1595-1599.
300. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B, Zhu Z, Zhao J, Ma A, Han Y, Wang Y, Shi Y, Ye J, Hui R; Multicenter Case-Control Study in China. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but meth-ylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a multicenter case-control study in China. Stroke 2003; 34: 2085-2090.
301. Zhang C, Shao Y, Hu X.Relationships between the plasma homocysteine levels and the polymorphisms of its metabolic enzymes and the cerebral infarction. Zhonghua Shen Jing Ge Za Zhi 2003; 36: 359-362.
302. Gao HF, Liu JG, Zhang ZC. Te relationship between hyper-homocysteinemia and MTHFR gene in young adult cerebral infarction patients. Tian Jin Yi Yao 2003; 10: 627-629.
303. Sun WP, Wan Qi, Su MQ. Genetic polymorphisms of 5,10- methylenetetrahydrofolate reductase (MTHFR) in patients with cerebral infarction. Zhong Hua Lao Nian Xin Nao Xue Guan Bing Za Zhi 2003; 5: 36-38.
304. Zhang Y, Xie RP, Wang YH. Study about association between MTHFR gene polymorphisms and cerebral infarction. Zhong Hua Shen Jing Ke Za Zhi 2003; 36: 73-74.
305. Baum L, Wong KS, Ng HK, Tomlinson B, Rainer TH, Chan DK, Tomas GN, Chen X, Poon P, Cheung WS, Woo KS. Methylenetetrahydrofolate reductase gene A222V polymorphism and risk of ischemic stroke. Clin Chem Lab Med 2004; 42: 1370-1376.
306. Uçar F, Sönmez M, Ovali E, Ozmenoglu M, Karti SS, Yilmaz M, Pakdemir A. MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. Am J Hematol 2004; 76: 40-43.
307. Fang L, Wu YQ, Wang TW. Correlation of polymorphism of gene methylenetetrahydrofolate reductase and cystathionine betasynthase with heredity of cerebral infarction and cerebral hemorrhage in northern Chinese Han people. Zhong Guo Kang Fu Za Zhi 2004; 8: 4654-4656.
308. Ye H, Yan JT, Shao JM. A case-control study on the relationship between stroke and plasma homocysteine level and the mutation of MTHFR gene. Zhong Hua Liu Xing Bing Xue Za Zhi 2004; 25: 958-962.
309. Alluri RV, Mohan V, Komandur S, Chawda K, Chaudhuri JR, Hasan Q. MTHFR C677T gene mutation as a risk factor for arterial stroke: a hospital-based study. Eur J Neurol 2005; 12: 40-44.
310. Fang X, Namba H, Akamine S, Sugiyama K. Methylenetetrahydrofolate reductase gene polymorphisms in patients with cerebral hemorrhage. Neurol Res 2005; 27: 73-76.
311. Kawamoto R, Kohara K, Oka Y, Tomita H, Tabara Y, Miki T. An association of 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and ischemic stroke. J Stroke Cerebrovasc Dis 2005; 14: 67-74.
312. Linnebank M, Montenarh M, Kölsch H, Linnebank A, Schnez K, Schweichel D, Pohl C, Urbach H, Heun R, Harbrecht U, Klockgether T, Wüllner U. Common genetic variants of homocysteine metabolism in ischemic stroke: a case-control study. Eur J Neurol 2005; 12: 614-618.
313. Szolnoki Z, Havasi V, Bene J, Komlósi K, Szöke D, Somogyvári F, Kondacs A, Szabo M, Fodor L, Bodor A, Gáti I, Wittman I, Melegh B. Endothelial nitric oxide synthase gene interactions and the risk of ischaemic stroke. Acta Neurol Scand 2005; 111: 29-33.
314. Qin MZ, Qin YZ. Correlation between Hcy and polymorphism of gene methylenetetrahydrofolate reductase and ischemic cerebral stroke. Zhong Guo Mei Tan Gong Ye Yi Xue Za Zhi 2005; 8: 474-475.
315. Dikmen M, Ozbabalik D, Gunes H V, Degirmenci I, Bal C, Ozdemir G, Basaran A. Acute stroke in relation to homo-cysteine and methylenetetrahydrofolate reductase gene polymorphism. Acta Neurol Scand 2006; 113: 307-314.
316. Li CM, Zhang C, Lu XL, Feng HY, Su QX, Zeng Y, Zhang HL, Qiu SL. Relationship between methylenetrahydrofolate reductase gene and ischemic stroke. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2006; 18: 264-267. (Pubitemid 43826637)
317. Pezzini A, Grassi M, Del Zotto E, Assanelli D, Archetti S, Negrini R, Caimi L, Padovani A. Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-disease analysis and genotype-disease analysis. J Neurol Neurosurg Psychiatry 2006; 77: 1150-1156.
318. Sánchez-Marín B, Grasa JM, Torres M, Calvo MT, Martínez-Jarreta B, García-Erce JA, Giralt M. Prevalence of methylene-tetrahydrofolate reductase C677T mutation among patients with acute ischemic cerebrovascular disease in Aragon. An Med Interna 2006; 23: 153-155.
319. Sazci A, Ergul E, Tuncer N, Akpinar G, Kara I. Methylenetetrahydrofolate reductase gene polymorphisms are associated with ischemic and hemorrhagic stroke: dual efect of MTHFR polymorphisms C677T and A1298C. Brain Res Bull 2006; 71: 45-50.
320. Szolnoki Z, Somogyvári F, Szabó M, Kondacs A, Fodor L, Melegh B. Interactions between the MTHFR C677T and MTHFR A1298C mutations in ischaemic stroke. Ideggyogy Sz 2006; 59: 107-112.
321. Xiao YQ, Jiang LL, Lu Q. Te relationship between the gene polymorphism of methylenetetrahydrofolate reductase and plasma homocysteine level with cerebrovascular disease. Jian Yan Yi Xue 2006; 21: 201-204.
322. Kim OJ, Hong SP, Ahn JY, Hong SH, Hwang TS, Kim SO, Yoo W, Oh D, Kim NK. Infuence of combined methionine synthase (MTR 2756A > G) and methylenetetrahydrofolate reductase (MTHFR 677C > T) polymorphisms to plasma homocysteine levels in Korean patients with ischemic stroke. Yonsei Med J 2007; 48: 201-209.
323. Li CM, Zhang C, Lu XL, Feng HY, Zeng Y, Zhang HL, Qiu SL. Association between angiotensin-converting enzyme and polymorphisms of N5, N10-methylenetetrahydrofolic acid reductase gene in patients with ischemic stroke. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2007; 29: 359-363.
324. Marie SK, Shinjo SK, Oba-Shinjo SM, de Silva R, Barbosa KC, Yamamoto F, Scaf M. Methylenetetrahydrofolate reductase gene polymorphism is not related to the risk of ischemic cer-ebrovascular disease in a Brazilian population. Clinics (Sao Paulo) 2007; 62: 295-300.
325. Pezzini A, Grassi M, Del Zotto E, Giossi A, Monastero R, Dalla Volta G, Archetti S, Zavarise P, Camarda C, Gasparotti R, Magoni M, Camarada R, Padovani A. Migraine mediates the infuence of C677T MTHFR genotypes on ischemic stroke risk with a stroke-subtype efect. Stroke 2007; 38: 3145-3151.
326. Szolnoki Z, Maasz A, Magyari L, Horvatovich K, Farago B, Somogyvari F, Kondacs A, Szabo M, Bodor A, Hadarits F, Melegh B. Te combination of homozygous MTHFR 677T and angiotensin II type-1 receptor 1166C variants confers the risk of small-vessel-associated ischemic stroke. J Mol Neurosci 2007; 31: 201-207.
327. Fang L, Wang TW, Shao YS, Yang H. Association between MTHFRC677T, CBS844ins68 polymorphism and young ischemic stroke. J Jilin Univ Med Ed 2007; 33: 310-313.
328. Zhang Y, Xie RP, Shen Y, Fan DS. Interaction between meth- ylenetetrahydrofolate reductase C677T gene polymorphism and sleep duration on risk of stroke pathogenesis. Beijing Da Xue Xue Bao 2008; 40: 262-269.
329. Schürks M, Zee RY, Buring JE, Kurth T. Interrelationships among the MTHFR 677C>T polymorphism, migraine, and cardiovascular disease. Neurology 2008; 71: 505-513.
330. Moe KT, Woon FP, De Silva DA, Wong P, Koh TH, Kingwell B, Chin-Dusting J, Wong MC. Association of acute ischemic stroke with the MTHFR C677T polymorphism but not with NOS3 gene polymorphisms in a Singapore population. Eur J Neurol 2008; 15: 1309-1314.
331. Gao J, Sun YF, Li YL, Su LK, Guo L. Hyperhomocysteine, genetic polymorphism of methylenetetra-hydrofolate reduct-ase in young adults with ischemic stroke. J Zhengzhou Univ Med Sci 2008; 43: 570-573.
332. Sabino A, Fernandes AP, Lima LM, Ribeiro DD, Sousa MO, de Castro Santos ME, Mota AP, Dusse LM, das Graças Carvalho M. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease. J Tromb Trombolysis 2009; 27: 82-87.
333. Goracy I, Cyryłowski L, Kaczmarczyk M, Fabian A, Koziarska D, Goracy J, Ciechanowicz A. C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of ischemic stroke in Polish subjects. J Appl Genet 2009; 50: 63-67.
334. Biswas A, Ranjan R, Meena A, Akhter MS, Yadav BK, Munisamy M, Subbiah V, Behari M, Saxena R. Homocystine levels, polymorphisms and the risk of ischemic stroke in young Asian Indians. J Stroke Cerebrovasc Dis 2009; 18: 103-110.
335. Fang L, Wu W, Wu YQ. Relationship between polymorphisms of cystathionine beta-synthase gene and stroke. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004; 16: 161-164.
336. Morita H, Kurihara H, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Tromb Vasc Biol 1999; 19: 298-302.
337. Souto JC, Blanco-Vaca F, Soria JM, Buil A, Almasy L, Ordoñez-Llanos J, Martin-Campos JM, Lathrop M, Stone W, Blangero J, Foncuberta J. A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project. Am J Hum Genet 2005; 76: 925-933.
338. Hankey GJ, Eikelboom JW. Homocysteine and stroke. Lancet 2005; 365: 194-196.
339. McCarron MO, Muir KW, Weir CJ, Dyker AG, Bone I, Nicoll JA, Lees KR. Te apolipoprotein E epsilon4 allele and outcome in cerebrovascular disease. Stroke 1998; 29: 1882-1887.
340. Stankovic S, Jovanovic-Markovic Z, Majkic-Singh N, Stankovic A, Gliic S, Ivkovic M, Kostic V, Alavantic D. Apolipoprotein E gene polymorphism as a risk factor for ischemic cerebrovascular disease. Jugoslov Med Biohem 2004; 23: 255-264.
341. McCarron MO, Delong D, Alberts MJ. ApoE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 1999; 53: 1308-1311.
342. Sudlow C, Martínez González NA, Kim J, Clark C. Does apoli-poprotein E genotype infuence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke 2006; 37: 364-370.
343. Mahieux F, Bailleul S, Fenelon R, Couderc R, Laruelle P, Gunel M. Prevalence of apolipoprotein E phenotypes in patients with acute ischemic stroke. Stroke 1990; 21: 1-115.
344. Pedro-Botet J, Sentí M, Nogues X, Rubiés-Prat J, Roquer J, D'Olhaberriague L, Olivé J. Lipoprotein and apolipoprotein profle in men with ischemic stroke. Role of lipoprotein (a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 1992; 23: 1556-1562.
345. Couderc R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. A case-control study. Stroke 1993; 24: 661-664.
346. Coria F, Rubio I, Nuñez E, Sempere AP, SantaEngarcia N, Bayón C, Cuadrado N. Apolipoprotein E variants in ischemic stroke. Stroke 1995; 26: 2375-2376.
347. De Andrade M, Tandi I, Brown S, Gotto A Jr, Patsch W, Boerwinkle E. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. Am J Hum Genet 1995; 56: 1379-1390.
348. Kuusisto J, Mykkänen L, Kervinen K, Kesäniemi YA, Laakso M. Apolipoprotein E4 phenotype is not an important risk factor for coronary heart disease or stroke in elderly subjects. Arterioscler Tromb Vasc Biol 1995; 15: 1280-1286.
349. Basun H, Corder EH, Guo Z, Lannfelt L, Corder LS, Manton KG, Winblad B, Viitanen M. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke 1996; 27: 1310-1315.
350. Hachinski V, Grafagnino C, Beaudry M, Bernier G, Buck C, Donner A, Spence JD, Doig G, Wolfe BM. Lipids and stroke: a paradox resolved. Arch Neurol 1996; 53: 303-308.
351. Ferrucci L, Guralnik JM, Pahor M, Harris T, Corti MC, Hyman BT, Wallace RB, Havlik RJ. Apolipoprotein E epsilon 2 allele and risk of stroke in the older population. Stroke 1997; 28: 2410-2416.
352. Nakata Y, Katsuya T, Rakugi H, Takami S, Sato N, Kamide K, Ohishi M, Miki T, Higaki J, Ogihara T. Polymorphism of angi-otensin converting enzyme, angiotensinogen, and apolipo-protein E genes in a Japanese population with cerebrovascular disease. Am J Hypertens 1997; 10: 1391-1395.
353. Schmidt R, Schmidt H, Fazekas F, Schumacher M, Niederkorn K, Kapeller P, Weinrauch V, Kostner GM. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke 1997; 28: 951-956. (Pubitemid 27209139)
354. Yang G, Jinjin G, Jianfei N. Te relationship between polymorphisms of Apolipoprotein E gene and atherosclerotic cerebral infarction. Zhonghua Shen Jing Ge Za Zhi 1997; 30: 236-239.
355. Wang DS, Jiang L, Dai YM. Primary study of ApoE gene polymorphism in patients with cerebral infarction. Zhong Feng Yu Shen Jing Ji Bing Za Zhi 1997; 14: 71-74.
356. Zhu TB, Zhao SP, You XK. Efect of apolipoprotein E gene on plasma levels of lipids, lipoprotein, apolipoprotein and relation to cerebral infarction. Hu Nan Yi Xue 1997; 14: 265-266.
357. Yan SK, Zhou X, Li XL. Relationship between gene polymorphism of apolipoprotein E and serum lipids, lipoproteins, and apolipoproteins in Chinese patients with atherothrom-botic brain infarction. Zhong Guo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi 1997; 4: 16-21.
358. Aalto-Setälä K, Palomäki H, Miettinen H, Vuorio A, Kuusi T, Raininko R, Salonen O, Kaste M, Kontula K. Genetic risk factors and ischaemic cerebrovascular disease: role of common variation of the genes encoding apolipoproteins and angiotensin-converting enzyme. Ann Med 1998; 30: 224-233.
359. Ji Y, Urakami K, Adachi Y, Maeda M, Isoe K, Nakashima K. Apolipoprotein E polymorphism in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease. Dement Geriatr Cogn Disord 1998; 9: 243-245.
360. Margaglione M, Seripa D, Gravina C, Grandone E, Vecchione G, Cappucci G, Merla G, Papa S, Postiglione A, Di Minno G, Fazio VM. Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: an Italian case-control study. Stroke 1998; 29: 399-403.
361. Cao W, Chen F, Teng L, Wang S, Fu S, Zhang G. Te relationship between apolipoprotein E gene polymorphism and coronary heart disease and arteriosclerotic cerebral infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 1999; 16: 249-251.
362. Peng DQ, Zhao SP, Wang JL. Lipoprotein (a), and apolipo-protein E4 as independent risk factors for ischemic stroke. J Cardiovasc Risk 1999; 6: 1-6.
363. Liu WG, Li ZH. Te relationship between polymorphisms of apolipoprotein E gene and atherosclerotic cerebral infarction in middle-aged and young adults. Lin Chuang Shen Jing Bing Xue Za Zhi 1999; 12: 134-136.
364. Peng DQ, Zhao SP. Comparison of apolipoprotein E genotype distribution in two types of stroke. Zhong Guo Dong Mai Ying Hua Za Zhi 1999; 7: 34-36.
365. Catto AJ, McCormack LJ, Mansfeld MW, Carter AM, Bamford JM, Robinson P, Grant PJ. Apolipoprotein E polymorphism in cerebrovascular disease. Acta Neurol Scand 2000; 101: 399-404.
366. Kokubo Y, Chowdhury AH, Date C, Yokoyama T, Sobue H, Tanaka H. Age-dependent association of apolipoprotein E genotypes with stroke subtypes in a Japanese rural population. Stroke 2000; 31: 1299-1306.
367. McCarron MO, Muir KW, Weir CJ, Dyker AG, Bone I, Nicoll JA, Lees KR. Te apolipoprotein E epsilon4 allele and outcome in cerebrovascular disease. Stroke 1998; 29: 1882-1887.
368. Ding J, Zhu WB, Fan W. Association between apolipoprotein E polymorphisms and cerebral stroke. Zhong Guo Shen Jing Jing Shen Ji Bing Za Zhi 2000; 26: 371-372.
369. Wang TG, He ZY, Li YQ. Te relation between apolipoprotein E gene polymorphism and atherosclerotic cerebral infarction. Yi Chuan 2000; 22: 4-6.
370. Chowdhury AH, Yokoyama T, Kokubo Y, Zaman MM, Haque A, Tanaka H. Apolipoprotein E genetic polymorphism and stroke subtypes in a Bangladeshi hospital-based study. J Epidemiol 2001; 11: 131-138.
371. Frikke-Schmidt R, Nordestgaard BG, Tudium D, Moes Grønholdt ML, Tybjaerg-Hansen A. ApoE genotype predicts AD and other dementia but not ischemic cerebrov-ascular disease. Neurology 2001; 56: 194-200.
372. MacLeod MJ, De Lange RP, Breen G, Meiklejohn D, Lemmon H, Clair DS. Lack of association between apolipo-protein E genoype and ischaemic stroke in a Scottish population. Eur J Clin Invest 2001; 31: 570-573.
373. Serteser M, Visvikis S, Ozben T, Herbeth B, Balkan S, Siest G. Lipid profle and apolipoprotein E genotyping in stroke: a case-control study. Neuroscience-Net 2001; 3: article 10015.
374. Slooter AJC, Bots ML, Havekes LM, del Sol AI, Cruts M, Grobbee DE, Hofman A, Van Broeckhoven C, Witteman JC, van Dujn CM. Apolipoprotein E and carotid artery atherosclerosis: the Rotterdam Study. Stroke 2001; 32: 1947-1952. (Pubitemid 32868077)
375. Li YW, He X, Zhao LX. Te relationship between polymorphisms of apolipoprotein E gene and cerebrovascular disorder. Xin Nao Xue Guan Bing Fang Zhi 2001; 1: 17-19.
376. Li ZH, LiuWG, Zhao XY, Chen YQ. Risk factor for stroke and ApoE polymorphism in the young and middle-aged. Cu Zhong Yu Shen Jing Ji Bing 2001; 8: 326-329.
377. Luthra K, Prasad K, Kumar P, Dwivedi M, Pandey RM, Das N. Apolipoprotein E gene polymorphism in cerebrovascular disease: a case-control study. Clin Genet 2002; 62: 39-44.
378. Morrison AC, Ballantyne CM, Bray M, Chambless LE, Sharrett AR, Boerwinkle E. LPL polymorphism predicts stroke risk in men. Genet Epidemiol 2002; 22: 233-242.
379. Shen LH, Ke KF, Li ZH. Research on apolipoprotein E gene polymorphism in patients with atherosclerotic cerebral infarction. Jiao Tong Yi Xue 2002; 16: 504-505.
380. Xia Y, Li HL, Wang JL. Association between apolipoprotein E polymorphism and lipid metabolism in patients with cerebral infarction. Zhong Guo Bing Li Sheng Li Za Zhi 2002; 18: 826-829.
381. Zhu L, Cui TP. Te relation of apolipoprotein E gene polymorphism and cerebral infarction. Xue Shuan Yu Zhi Xue Xue 2002; 8: 14-15.
382. Kolovou GD, Daskalova DCh, Hatzivassiliou M, Yiannakouris N, Pilatis ND, Elisaf M, Mikhailidis D P, Cariolou MA, Cokkinos DV. Te epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population\implications for the interpretation of similar studies. Angiology 2003; 54: 51-58.
383. Slowik A, Iskra T, Turaj W, Hartwich J, Dembinska-Kiec A, Szczudlik A. LDL phenotype B and other lipid abnormalities in patients with large vessel disease and small vessel disease. J Neurol Sci 2003; 214: 11-16.
384. Souza DR, Campos BF, de Arruda EF, Yamamoto LJ, Trinidane DM, Tognola WA. Infuence of the polymorphism of apolipoprotein E in cerebral vascular disease. Arq Neuropsiquiatr 2003; 61: 7-13.
385. Um JY, Kim HM, Park HS, Joo JC, Kim KY, Kim YK, Hong SH. Candidate genes of cerebral infarction and traditional clas-sifcation in Koreans with cerebral infarction. Int J Neurosci 2005; 115: 743-756.
386. Wang XT, Huang HJ, Ju K. Apolipoprotein E gene polymorphism in people with cerebrovascular disease in the south of the Zhejiang province. Shen Jing Ji Bing Yu Jing Shen Wei Sheng 2003; 3: 17-19.
387. Duzenli S, Pirim I, Gepdiremen A, Deniz O. Apolipoprotein E polymorphism and stroke in a population from eastern Turkey. J Neurogenet 2004; 18: 365-375.
388. Jin ZQ, Fan YS, Ding J, Chen M, Fan W, Zhang GJ, Zhang BH, Yu SJ, Zhang YS, Ji WF, Zhang JG. Association of apolipopro-tein E 4 polymorphism with cerebral infarction in Chinese Han population. Acta Pharmacol Sin 2004; 25: 352-356.
389. Lin HF, Lai CL, Tai CT, Lin RT, Liu CK. Apolipoprotein E poly-morpshim in ischemic cerebrovascular diseases and vascular dementia patients in Taiwan. Neuroepidemiology 2004; 23:129-134.
390. Pezzini A, Grassi M, Zotto ED, Bazzoli E, Archetti S, Assanelli D, Akkawi NM, Albertini A, Padovani A. Synergistic efect of apolipoprotein E polymorphisms and cigarette smoking on risk of ischemic stroke in young adults. Stroke 2004; 35: 438-442.
391. Stankovic S, Jovanovic-Markovic Z, Majkic-Singh N, Stankovic A, Gliic S, Ivkovic M, Kostic V, Alavantic D. Apolipoprotein E gene polymorphism as a risk factor for ischemic cerebrovascular disease. Jugoslov Med Biohem 2004; 23: 255-264.
392. Cerrato P, Baima C, Grasso M, Lentini A, Bosco G, Cassader M, Gambino R, Cavallo Perin P, Pagano G, Fornengo P, Imperiale D, Bergamasco B, Bruno G. Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort. Cerebrovasc Dis 2005; 20: 264-269.
393. Zhou J, Xue YL, Guan YX, Yang YD, Fu SB, Zhang JC. Association study of apolipoprotein e gene polymorphism and cerebral infarction in type 2 diabetic patients. Yi Chuan 2005; 27: 35-38.
394. Baum L, Ng HK, Wong KS, Tomlinson B, Rainer TH, Chen X, Cheung WS, Tang J, Tam WWS, Goggins W, Tong CSW, Kam D, Chan Y, Tomas GN, Chook P, Woo KS. Associations of apoli-poprotein E exon 4 and lipoprotein lipase S447X polymorphisms with acute ischemic stroke and myocardial infarction. Clin Chem Lab Med 2006; 44: 274-281.
395. Kang SY, Lee WI. Apolipoprotein e polymorphism in ischemic stroke patients with diferent pathogenetic origins. Korean J Lab Med 2006; 26: 210-216.
396. Jiang ZQ, Liu H, Zhang GZ. Relationship between polymorphism of apolipoprotein E gene and atherosclerotic cerebral infarction, hypertensive intracerebral hemorrhage in the youth. J Gannan Med Univ 2006; 26: 331-334.
397. Wang JH, Ning XJ, Lu HY. Te study on apolipoprotein E gene polymorphism characteristics of cerebral infarction and intracerebral hemorrhage. Zhong Guo Man Xing Bing Yu Fang Yu Kong Zhi 2006; 14: 21-23.
398. Giassakis G, Veletza S, Papanas N, Heliopoulos I, Piperidou H. Apolipoprotein E and frst-ever ischaemic stroke in Greek hospitalized patients. J Int Med Res 2007; 35: 127-133.
399. Lai CL, Liu CK, Lin RT, Tai CT. Association of apolipoprotein E polymorphism with ischemic stroke subtypes in Taiwan. Kaohsiung J Med Sci 2007; 23: 491-497.
400. Parfenov MG, Nikolaeva TY, Sudomoina MA, Fedorova SA, Guekht AB, Gusev EI, Favorova OO. Polymorphism of apoli-poprotein E (APOE) and lipoprotein lipase (LPL) genes and ischaemic stroke in individuals of Yakut ethnicity. J Neurol Sci 2007; 255: 42-49.
401. Saidi S, Slamia LB, Ammou SB, Mahjoub T, Almawi WY. Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels. J Stroke Cerebrovasc Dis 2007; 16: 160-166.
402. Abboud S, Viiri LE, Lütjohann D, Goebeler S, Luoto T, Friedrichs S, Desfontaines P, Gazagnes MD, Laloux P, Peeters A, Seeldrayers P, Lehtimaki T, Karhunen P, Pandolfo M, Laaksonen R. Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis. Eur J Hum Genet 2008; 16: 955-960.
403. Artieda M, Gañán A, Cenarro A, García-Otín AL, Jericó I, Civeira F, Pocoví M. Association and linkage disequilibrium analyses of APOE polymorphisms in atherosclerosis. Dis Markers 2008; 24: 65-72
404. Tasdemir N, Tamam Y, Toprak R, Tamam B, Tasdemir MS. Association of apolipoprotein E genotype and cerebrovascu-lar disease risk factors in a Turkish population. Int J Neurosci 2008; 118: 1109-1129.
405. Wang B, Zhao H, Zhou L, Dai X, Wang D, Cao J, Niu W. Association of genetic variation in apolipoprotein E and low density lipoprotein receptor with ischemic stroke in Northern Han Chinese. J Neurol Sci 2009; 276: 118-122.
406. Saidi S, Zammiti W, Slamia LB, Ammou SB, Almawi WY, Mahjoub T. Interaction of angiotensin-converting enzyme and apolipoprotein E gene polymorphisms in ischemic stroke involving large-vesssel disease. J Tromb Trombolysis 2009; 27: 68-74.
407. Tascilar N, Dursun A, Ankarali H, Mungan G, Sumbuloglu V, Ekem S, Bozdogan S, Baris S, Aciman E, Cabuk F. Relationship of apoE polymorphism with lipoprotein(a), apoA, apoB and lipid levels in atherosclerotic infarct. J Neurol Sci 2009; 277: 17-21.
408. Wang L, Gu Y, Wu G, Wang W, Liu J, Liu J, Wu Z. A case control study on the distribution of apolipoprotein AI gene polymorphisms in the survivors of atherosclerosis cerebral infarction. Zhonghua Liu Xing Bing Xue Za Zhi 2000; 21: 22-25.
409. Havasi V, Szolnoki Z, Talián G, Bene J, Komlósi K, Maász A, Somogyvári F, Kondacs A, Szabó M, Fodor L, Bodor A, Melegh B. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglycer-ide levels and confers susceptibility of ischemic stroke. J Mol Neurosci 2006; 29: 177-183.
410. Li J, Xu, Zhu XY. Association of APOA5 gene polymorphism with levels of lipids and atherosclerotic cerebral infarction in Chinese. Zhonghua Yi Xue Yi Chuam Xue Za Zhi 2007; 24: 576-578.
411. Zhang K, Qiu F, Li L, Gu GY, Tao Y, Wang L, Luo XY, Xia YQ. Te associated study on apolipoprotein A5 gene polymorphisms with carotid artherosclerosis in patients with cerebral infartion. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008; 25: 284-288.
412. Járomi L, Csöngei V, Polgár N, Szolnoki Z, Maász A, Horvatovich K, Faragó B, Sipeky C, Sáfrány E, Magyari L, Kisfali P, Mohás M, Janicsek I, Lakner L, Melegh B. Functional variants of glucokinase regulatory protein and apolipopro-tein A5 genes in ischemic stroke. J Mol Neurosci 2010; 41: 121-128.
413. Wang L, Gu Y, Wu G. Te relation between polymorphisms of apolipoprotein B gene and atherosclerotic cerebral infarction. Zhonghua Yi Xue Za Zhi 1999; 79: 603-606.
414. Stankovic A, Stankovic S, Jovanovic-Markovic Z, Zivkovic M, Djuric T, Gliic-Milosavljevic S, Alavantic D. Apolipoprotein B gene polymorphisms in patients from Serbia with ischemic cerebrovascular disease. Arch Biol Sci 2007; 59: 303-309.
415. Xia J, Yang Q, Yang Q, Xu H, Zhang L. Te relationship of apolipoprotein H G1025C (Try316Ser) polymorphism with stroke and its efect on plasma lipid levels in Changsha Hans. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003; 20: 114-118.
416. Hu B, Zhou X, Shao H. Relationship between pentanucleotide repeat polymorphism of apolipoprotein (a) gene and atherosclerosis cerebral infarction in Han nationality. Zhonghua Shen Jing Ge Za Zhi 2000; 33: 172-175.
417. Liu X, Sun L, Li Z, Gao Y, Hui R. Relation of pentanucleotide repeat polymorphism of apolipoprotein (a) gene to plasma lipoprotein (a) level among Chinese patients with myocardial infarction and cerebral infarction. Zhonghua Yi Xue Za Zhi 2002; 82: 1396-1400.
418. Sun L, Li Z, Zhang H, Ma A, Liao Y, Wang D, Zhao B, Zhu Z, Zhao J, Zhang Z, Wang W, Hui R. Pentanucleotide TTTTA repeat polymorphism of apolipoprotein(a) gene and plasma lipoprotein(a) are associated with ischemic and hemorrhagic stroke in Chinese: a multicenter case-control study in China. Stroke 2003; 34: 1617-1622. (Pubitemid 36842613)
419. Ogorelkova M, Kraft HG, Ehnholm C, Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain afect Lp(a) plasma concentrations and have diferent patterns in Africans and Caucasians. Hum Mol Genet 2001; 10: 815-824.
420. Trommsdorf M, Köchl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, Lemming L, Klausen IC, Faergeman O, Utermann G, Kraft HG. A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein (a) gene is associated with lipoprotein (a) plasma concentrations in Caucasians. J Clin Invest 1995; 96: 150-157.
421. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PW, Schaefer EJ. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Tromb Vasc Biol 2000; 20: 1323-1329.
422. Brousseau ME, O'Connor JJ Jr, Ordovas JM, Collins D, Otvos JD, Massov T, McNamara JR, Rubins HB, Robins SJ, Schaefer EJ. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL defciency: Veterans Afairs HDL Cholesterol Intervention Trial. Arterioscler Tromb Vasc Biol 2002; 22: 1148-1154.
423. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijf P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ; Te Regression Growth Evaluation Statin Study Group. Te role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 86-93.
424. Elosua R, Cupples LA, Fox CS, Polak JF, D'Agostino RA Sr, Wolf PA, O'Donnell CJ, Ordovas JM. Association between well-characterized lipoprotein-related genetic variants and carotid intimal medial thickness and stenosis: the Framingham Heart Study. Atherosclerosis 2006; 189: 222-228.
425. Meguro S, Takei I, Murata M, Hirose H, Takei N, Mitsuyoshi Y, ishii K, Oguchi S, Shinohara J, Takeshita E, Watanabe K, Saruta T. Cholesteryl ester transfer protein polymorphism associated with macroangiopathy in Japanese patients with type 2 diabetes. Atherosclerosis 2001; 156: 151-156.
426. Asselbergs FW, Moore JH, van den Berg MP, Rimm EB, de Boer RA, Dullaart RP, Navis G, van Gilst WH. A role for CETP TaqIB polymorphism in determining susceptibility to atrial fbrillation: a nested case control study. BMC Med Genet 2006; 7: 39.
427. Zhuang Y, Wang J, Qiang H, Li Y, Liu X, Li L, Chen G. Cholesteryl ester transfer protein levels and gene defciency in Chinese patients with cardio-cerebrovascular diseases. Chin Med J (Engl) 2002; 115: 371-374.
428. Fidani L, Hatzitolios AI, Goulas A, Savopoulos C, Basayannis C, Kotsis A. Cholesterlyl ester transfer protein TaqI B and lipoprotein lipase Ser447Ter gene polymorphisms are not associated with ischaemic stroke in Greek patients. Neurosci Lett 2005; 384: 102-105.
429. Quarta G, Stanzione R, Evangelista A, Zanda B, Sciarretta S, Di Angelantonio E, Marchitti S, Di Murro D, Volpe M, Rubattu S. A protective role of a cholesteryl ester transfer protein gene variant towards ischaemic stroke in Sardinians. J Int Med 2007; 262: 555-561.
430. Enquobahrie DA, Smith NL, Bis JC, Carty CL, Rice KM, Lumley T, Hindorf LA, Lemaitre RN, Williams MA, Siscovick DS, Heckbert SR, Psaty BM. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am J Cardiol 2008; 101: 1683-1688.
431. Hindorf LA, Lemaitre RN, Smith NL, Bis JC, Marciante KD, Rice KM, Lumley T, Enquobahrie DA, Li G, Heckbert SR, Psaty BM. Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet Genomics 2008; 18: 677-682.
432. Von Eckardstein A, Nofer JR, Assman G. High density lipo-proteins and atherosclerosis. Role of cholesterol efux and reverse cholesterol transport. Arterioscler Tromb Vasc Biol 2001; 21: 13-27.
433. Braunham LR, Singaraja RR, Hayden MR. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu Rev Nutr 2006; 26: 105-129.
434. Andrikovics H, Pongrácz E, Kalina E, Szilvási A, Aslanidis C, Schmitz G, Tordai I. Decreased frequencies of ABCA1 polymorphisms R219K and V771M in Hungarian patients with cerebrovascular and cardiovascular diseases. Cerebrovasc Dis 2006; 21: 254-259.
435. Pasdar A, Yadegarfar G, Cumming A, Whalley L, St Clair D, MacLeod MJ. Te efect of ABCA1 gene polymorphisms on ischaemic stroke risk and relationship with lipid profle. BMC Med Genetics 2007; 8: 30-36.
436. Yamada Y, Metoki N, Yoshida H, Satoh K, Kato K, Hibino T, Yokoi K, Watanabe S, Ichihara S, Aoyagi Y, Yasunaga A, Park H, Tanaka M, Nozawa Y. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke 2008; 39: 2211-2218.
437. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320: 1060-1068.
438. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptorrelated protein. Proc Natl Acad Sci USA 1991; 88: 8342-8346.
439. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipopro-teins, and risk of ischemic heart disease.
440. Kastelein JJ, Ordovas JM, Wittekoek ME, Pimstone SN, Wilson WF, Gagné SE, Larson MG, Schaefer EJ, Boer JM, Gerdes C, Hayden MR. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their infuence on plasma lipids and lipoproteins in men and women. Clin Genet 1999; 56: 297-305.
441. Chamberlain JC, Torn JA, Oka K, Galton DJ, Stocks J. DNA polymorphisms at the lipoprotein lipase gene: associations in normal and hypertriglyceridaemic subjects. Atherosclerosis 1989; 79: 85-91. (Pubitemid 19219633)
442. Gerdes C, Gerdes LU, Hansen PS, Faergeman O. Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men. Circulation 1995; 92: 1765-1769.
443. Shimo-Nakanishi Y, Urabe T, Hattori N, Watanabe Y, Nagao T, Yokochi M, Hamamoto M, Mizuno Y. Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese. Stroke 2001; 32: 1481-1486.
444. Huang P, Kostulas K, Huang WX, Crisby M, Kostulas V, Hillert J. Lipoprotein lipase gene polymorphisms in ischae-mic stroke and carotid stenosis. Eur J Clin Invest 1997; 27: 740-742.
445. Wittrup HH, Nordestgaard BG, Sillesen H, Schnohr P, Tybjaerg-Hansen A. A common mutation in lipoprotein lipase confers a 2-fold increase in risk of ischemic cerebrov-ascular disease in women but not in men. Circulation 2000; 101: 2393-2397.
446. Myllykangas L, Polvikoski T, Sulkava R, Notkola IL, Rastas S, Verkkoniemi A, Tienari PJ, Niinistö L, Hardy J, Pérez-Tur J, Kontula K, Haltia M. Association of lipoprotein lipase Ser447Ter polymorphism with brain infarction: a population-based neuropathological study. Ann Med 2001; 33: 486-492.
447. Zhao SP, Tong QG, Xiao ZJ, Cheng YC, Zhou HN, Nie S. Te lipoprotein lipase Ser447Ter mutation and risk of stroke in the Chinese. Clin Chim Acta 2003; 330: 161-164.
448. Guan GD, Xu E, Wang XJ, Xu YH, Qiu SD. Associations between Ser447Ter gene polymorphism of lipoprotein lipase and atherosclerotic cerebral infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006; 23: 519-522. (Pubitemid 44622625)
449. Kostulas K, Brophy VH, Moraitis K, Manolescu A, Kostulas V, Gretarsdottir S, Cheng S, Hillert J. Genetic profle of ischemic cerebrovascular disease and carotid stenosis. Acta Neurol Scand 2008; 118: 146-152.
450. Xu E, Li W, Zhan L, Guan G, Wang X, Chen S, Shi Y. Polymorphisms of the lipoprotein lipase gene are associated with atherosclerotic cerebral infarction in the Chinese. Neuroscience 2008; 155: 403-408.
451. Tang X, Zhu YP, Li N, Chen DF, Zhang ZX, Dou HD, Hu YH. Genetic epidemiological study on discordant sib pairs of ischemic stroke in Beijing Fangshan District. Beijing Da Xue Xue Bao 2007; 39: 119-125.
452. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is diferent from that required for Its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Tromb Vasc Biol 1998; 18: 1617-1624.
453. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
454. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. Te human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33: 498-507.
455. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective efect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
456. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Tromb Vasc Biol 2001; 21: 542-547.
457. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modifcation of low density lipoprotein. J Biol Chem 2001; 276: 44444-44449.
458. Cao H, Girard-Globa A, Serusclat A, Bernard S, Bondon P, Picard S, Berthezene F, Moulin P. Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis 1998; 138: 361-366.
459. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000; 149: 435-442.
460. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxonase 192 Gln-Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002; 33: 1459-1464.
461. Ueno T, Shimazaki E, Matsumoto T, Watanabe H, Tsunemi A, Takahashi Y, Mori M, Hamano R, Fujioka T, Soma M, Matsumoto K, Kanmatsuse K. Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese populations. Med Sci Monit 2003; 9: CR208-CR212.
462. Chen JH, Zeng QX. Relationship between the paraoxonase gene 192 polymorphism and atherosclerotic cerebral infarction. Zhong Guo Lin Chuang Kang Fu 2003; 7: 3036-3037.
463. Ranade K, Kirchgessner TG, Iakoubova OA, Devlin JJ, DelMonte T, Vishnupad P, Hui L, Tsuchihashi Z, Sacks FM, Sabatine MS, Braunwald E, White TJ, Shaw PM, Dracopoli NC. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonse 1 gene is associated with increased risk of stroke. Stroke 2005; 36: 2346-2350.
464. Huang Q, Liu YH, Yang Q. Te association of PON1 Q192R gene polymorphism with atherosclerotic cerebral infarction. Zhong Hua Shen Jing Ke Za Zhi 2005; 38: 454-455.
465. Wu J, Zhao SP, Tan LM. Te relationship between PON1-192 polymorphism and type of cerebral infarction. Nao Yu Shen Jing Ji Bing Za Zhi 2005; 13: 253-255.
466. Yu LT, Yu DC, Li L. Te relationship between paraoxonase gene 192Gln/Arg polymorphism and ischemic cerebrovas-cular disease. Zhong Hua Lao Nian Xin Nao Xue Guan Bing Za Zhi 2005; 7: 254-256.
467. Baum L, Ng HK, Woo KS, Tomlinson B, Rainer TH, Chen X, Cheung WS, Chan DK, Tomas GN, Tong CS, Wong KS. Paraoxonase 1 gene Q192R polymorphism afects stroke and myocardial infarction risk. Clin Biochem 2006; 39: 191-195.
468. Huang Q, Liu YH, Yang QD, Xiao B, Ge L, Zhang N, Xia J, Zhang L, Liu ZJ. Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population. Neurol Res 2006; 28: 549-554.
469. Pasdar A, Ross-Adams H, Cumming A, Cheung J, Whalley L, St Clair D, MacLeod MJ. Paraoxonase gene polymorphism and haplotype analysis in a stroke population. BMC Medical Genetics 2006; 7: 28-33.
470. Aydin M, Gencer M, Cetinkaya Y, Ozkok E, Ozbek Z, Kilic G, Orken C, Tireli H, Kara I. PON1 55/192 polymorphism, oxida-tive stress, type, prognosis and severity of stroke. IUBMB Life 2006; 58: 165-172.
471. Chen WR, Xiao ZJ, Zhao SQ. Te relationship between the gene polymorphism in paraoxonase and lacunar infarction. Cu Zhong Yu Shen Jing Ji Bing 2006; 13: 75-78.
472. Schiavon R, Turazzini M, De Fanti E, Battaglia P, Targa L, Del Colle R, Fasolin A, Silvestri M, Biasioli S, Guidi G. PON1 activity and genotype in patients with arterial ischemic stroke and in healthy individuals. Acta Neurol Scand 2007; 116: 26-30.
473. Shin BS, Oh SY, Kim YS, Kim KW. Te paraoxonase gene polymorphism in stroke patients and lipid profle. Acta Neurol Scand 2008; 117: 237-243.
474. Slowik A, Wloch D, Szermer P, Wolkow P, Malecki M, Pera J, Turaj W, Dziedzic T, Klimkowicz-Mrowiec A, Kopec G, Figlewicz DA, Szczudlik A. Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disese stroke in a Polish population. Cerebrovasc Dis 2007; 23: 395-400.
475. Demirdögen BC, Türkanoglu A, Bek S, Sanisoglu Y, Demirkaya S, Vural O, Arinç E, Adali O. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 2008; 41: 1-9.
476. Demirdögen BC, Demirkaya S, Türkanoglu A, Bek S, Arinç E, Adali O. Analysis of paraoxonase 1 (PON1) genetic polymorphisms and activities as risk factors for ischemic stroke in Turkish population. Cell Biochem Funct 2009; 27: 558-567.
477. Xiao ZJ, Chen J, Sun Y, Zheng ZJ. Lack of association between the paraoxonase 1 Q/R192 single nucleotide polymorphism and stroke in a Chinese cohort. Acta Neurol Belg 2009; 109: 205-209.
478. Schmidt R, Schmidt H, Fazekas F, Kapeller P, Roob G, Lechner A, Kostner GM, Hartung HP. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the Austrian Stroke Prevention Study. Arterioscler Tromb Vasc Biol 2000; 20: 1811-1816.
479. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J. Te combined efect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 2004; 61: 351-356.
480. Xu HW, Zhao Z, Yuan N, Xiao B, Yang XS, Tang BS. Relationship between single nucleotide polymorphisms of paraoxonase 2 and stroke. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007; 24: 328-330.
481. Guo Y, Guo J, Zheng D, Pan L, Li Q, Ruan G. Relationship between the Nco I, Ava II polymorphism of low density lipoprotein receptor gene and atherosclerotic cerebral infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002; 19: 209-212.
482. Frikke-Schmidt R, Nordestgaard BG, Schnohr P, Tybjærg-Hansen A. Single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. A case-control and prospective study. Eur Heart J 2004; 25: 943-951.
483. Vieira JRS, Whittall RA, Cooper JA, Miller GJ, Humphries SE. The A370T variant (StuI polymorphism) in the LDL receptor gene is not associated with plasma lipid levels or cardiovascular risk in UK men. Ann Hum Genet 2006; 70: 697-704.
484. Lee JD, Lin YH, Hsu HL, Huang YC, Wu CY, Ryu SJ, Lee M, Huang YC, Hsiao MC, Chang YJ, Chang CH, Lee TH. Genetic polymorphisms of low density lipoprotein receptor can modify stroke presentation. Neurol Res 2010; 32: 535-540.
485. Hattori H, Sonoda A, Sato H, Ito D, Tanahashi N, Murata M, Saito I, Watanabe K, Suzuki N. G501C polymorphism of oxidized LDL receptor geen (OLR1) and ischemic stroke. Brain Res 2006; 1121: 246-249.
486. Wang WYS, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005; 6: 109-118.
487. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common dis eases and 3,000 shared controls. Nature 2007; 447: 661-678.
488. Matarin M et al. A genome-wide genotyping study in patients with ischemic stroke: inicial analysis and data release. Lancet Neurol 2007; 6: 414-420.
489. Ikram MA et al. Genomewide association studies of stroke. N Engl J Med 2009; 360: 1718-1728.